The Thermodynamics of Ligand Association and Molecular Recognition of Cationic and Metallated Porphyrins and Ruthenium Complexes with Model DNA Constructs by DuPont, Jesse I
Mississippi State University 
Scholars Junction 
Theses and Dissertations Theses and Dissertations 
1-1-2016 
The Thermodynamics of Ligand Association and Molecular 
Recognition of Cationic and Metallated Porphyrins and Ruthenium 
Complexes with Model DNA Constructs 
Jesse I. DuPont 
Follow this and additional works at: https://scholarsjunction.msstate.edu/td 
Recommended Citation 
DuPont, Jesse I., "The Thermodynamics of Ligand Association and Molecular Recognition of Cationic and 
Metallated Porphyrins and Ruthenium Complexes with Model DNA Constructs" (2016). Theses and 
Dissertations. 4676. 
https://scholarsjunction.msstate.edu/td/4676 
This Dissertation - Open Access is brought to you for free and open access by the Theses and Dissertations at 
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of 
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com. 
Template C with Schemes v3.0 (beta): Created by J. Nail 06/2015  
The thermodynamics of ligand association and molecular recognition of cationic and 
metallated porphyrins and ruthenium complexes with model DNA constructs 
By 
TITLE PAGE 
Jesse Isaac DuPont 
A Dissertation 
Submitted to the Faculty of 
Mississippi State University 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy 
in Chemistry 
in the Department of Chemistry 










The thermodynamics of ligand association and molecular recognition of cationic and 
metallated porphyrins and ruthenium complexes with model DNA constructs 
By 
APPROVAL PAGE 
Jesse Isaac DuPont 
Approved: 
 ____________________________________ 
Edwin A. Lewis 
(Major Professor) 
 ____________________________________ 
Joseph P. Emerson 
(Committee Member) 
 ____________________________________ 






Keith T. Mead 
(Committee Member) 
 ____________________________________ 





College of Arts & Sciences 
 
 
Name: Jesse Isaac DuPont 
ABSTRACT 
Date of Degree: August 12, 2016 
Institution: Mississippi State University 
Major Field: Chemistry 
Major Professor: Edwin A. Lewis 
Title of Study: The thermodynamics of ligand association and molecular recognition of 
cationic and metallated porphyrins and ruthenium complexes with model 
DNA constructs 
Pages in Study 149 
Candidate for Degree of Doctor of Philosophy 
Molecular recognition, particularly as it applies to strong binding interactions 
between complementary ligand/receptor molecules in solution, is important in such 
varied areas as molecular biology, pharmacology, synthetic chemistry, and chemical 
detection. Strong binding is the additive result of a number of specific, weak, non-
covalent interactions occurring between complementary molecules. This dissertation 
reports on the energetics of forming complexes between small molecules and model 
DNA constructs. Ligands included cationic and metallated cationic porphyrins and 
polyheterocyclic ruthenium compounds. DNA receptors included double stranded B-
DNAs (hairpin and short linear sequences) as well G-quadruplex DNAs. Thermodynamic 
data were collected using isothermal titration calorimetry, circular dichroism 
spectropolarimetry, ultraviolet-visible spectroscopy, and mass spectrometry. The 
measured thermodynamic parameters included the changes in free energy, enthalpy and 
entropy for ligand/receptor complex formation as well as the stoichiometry of the stable 
complexes. The first section of this dissertation reports that the binding of cationic 
porphyrins to model G-quadruplex DNA may proceed through two pathways, end 
 
 
stacking and intercalation. Modulating the number of pyridinium groups on a pyridinium 
substituted porphyrin yielded differing binding thermodynamics leading to the 
understanding that a balance of surface area, charge, and geometry affect the ability of a 
porphyrin to bind to G-quadruplex DNA. Further investigations into the binding of 
metallated porphyrins developed the understanding that the geometry of the central metal 
ion affected not only the thermodynamics but could also inhibit the intercalative mode. It 
was previously shown that the high affinity binding for binuclear polyheterocyclic 
ruthenium compounds proceeds through an intercalative mode. To further understand the 
binding process and the structure-function relationship of the ligand components, the 
binding of smaller mononuclear complexes that were representative of portions of the 
binuclear complex was examined in this dissertation. While limiting the intercalative 
ability lowered the binding affinity, the mononuclear complex with the full intercalating 
bridge was able bind to DNA with a higher affinity than the binuclear complex. These 
studies have been successful in part in determining the contributions of numerous weak 
interactions including: charge (Coulombic interactions), H-bonding, hydrophobic 
interactions, and solvent structure (solvation changes), to the overall energetics of this 
molecular recognition process. The first section of this dissertation reports that the 
binding of cationic porphyrins to model G-quadruplex DNA may proceed through two 
pathways, end stacking and intercalation. Modulating the number of pyridinium groups 
on a pyridinium substituted porphyrin yielded differing binding thermodynamics leading 
to the understanding that a balance of surface area, charge, and geometry affect the ability 
of a porphyrin to bind to G-quadruplex DNA. Further investigations into the binding of 
metallated porphyrins developed the understanding that the geometry of the central metal 
 
 
ion affected not only the thermodynamics but could also inhibit the intercalative mode. It 
was previously shown that the high affinity binding for binuclear polyheterocyclic 
ruthenium compounds proceeds through intercalation. To further understand the binding 
process and the structure-function relationship of the ligand components, the binding of 
smaller mononuclear complexes that were representative of portions of the binuclear 
complex was examined in this dissertation. While limiting the intercalative ability 
lowered the binding affinity, the mononuclear complex with the full intercalating bridge 
was able bind to DNA with a higher affinity than the binuclear complex. These studies 
have been successful in part in determining the contributions of numerous weak 
interactions including: charge (Coulombic interactions), H-bonding, hydrophobic 
interactions, and solvent structure (solvation changes), to the overall energetics of this 
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Cancer is the second most prevalent cause of death in the United States (1).  The 
cellular basis for cancer, malignancy, occurs when damage to a cell’s deoxyribonucleic 
acid (DNA) is greater than cellular repair ability. Primary views on the “hallmarks of 
cancer” established the following characteristics: sustaining proliferative signaling, 
enabling replicative immortality, inducing angiogenesis (formation of new blood vessels 
for the transport of nutrients), evading growth suppressors, resisting cell death, and 
activating invasion and metastasis (the spread of cancer from one location to another, e.g. 
liver to lung) (2).  Recent “emerging hallmarks” have been added to the list: deregulating 
cellular energetics, avoiding immune destruction, genome instability and mutation, and 
tumor-promoting inflammation (3).  While the emerging hallmarks have similarities to 
and basis in the seminal hallmarks, both groups offer insight into possible treatment 
mechanisms. As cancer is often caused by mutations within the genome, DNA offers an 
attractive target for therapies (4, 5).  
1.2 Introduction to deoxyribonucleic acid (DNA) 
DNA is possibly the most important aspect of an organism.  This 
biomacromolecule codes for everything that an organism is or will become.  The 
principal structure of DNA within a cell is that of its tertiary, double helical structure of 
 
2 
antiparallel strands as discovered by Watson and Crick (6).  Hydrogen bonding between 
complementary purine and pyrimidine bases stabilizes this double helical structure (6, 7).  
The hydrogen bonding can primarily be seen between the purines adenine and guanine 
with the pyrimidines thymine and cytosine respectively.  Three main types of DNA exist: 
A, B, and Z-form DNA (Figure 1.1).  Of the three the most prevalent form of DNA, B-
DNA, is most often used as a therapeutic target (8). Other, noncanonical intermolecular 
and intramolecular DNA structures are believed to exist in vivo including G-quadruplex, 
I-motif, triplex, hairpin, and cruciform DNA structures (9-11). 
DNA has two primary responsibilities: replication, the semiconservative process 
by which two molecules of daughter DNA are formed from the parent DNA, as 
illustrated in Figure 1.2, and transcription, the process by which the DNA’s coding is 
copied by messenger RNA (mRNA) to be translated into specific amino acid sequences 
to code for proteins, as illustrated in Figure 1.3 (9).  Errors in either process may be 
phenotypically silent or may have dire consequences for the function of the organism and 
cause disease (3, 4).  The binding of molecules to DNA is of intense interest in 
understanding the formation of diseases, as well as how to treat them (12).  The sequence 
of the nucleotides that make up DNA allows distinct functional environments that 
influence the binding of other molecules to DNA, including environments that allow 
intercalation, negatively charged binding areas for cations, and grooves that allow for the 




Figure 1.1  Stick structures of double helical DNA conformation.   
Reproduced with permission from Wood, B. R., The importance of hydration and DNA 
conformation in interpreting spectra of cells and tissues. Chemical Society Reviews 2016 
45 (7) 1980-1998. 
A) Stick diagram of A-DNA B) Stick diagram of B-DNA C) Stick diagram of Z-DNA.  
A-DNA is characterized by a widened minor groove relative to B-DNA and exhibits a 
complete turn every 11 base pairs, with base pairs being angled roughly 20 degrees from 
the axis perpendicular to the helical axis. The base pairs are separated with a distance of 
2.55 Å.  B-DNA exhibits a smaller minor groove and a larger major groove with 10.5 
base pairs comprising a complete turn and a diameter of 20 Å.  Distances between B-
DNA base pairs are 3.4 Å.  While A- and B-DNA are right handed, Z-DNA is 
characterized by a left handed double helical conformation with bases extending beyond 
the core of the helix and the presence of only one groove.  One complete turn of Z-DNA 







Figure 1.2 Model of the replication of DNA. Image created by Mariana Ruiz and is 
released to the public domain. 
Topoisomerase causes a transient nicking of the DNA backbone to release the supercoil 
causing helical tension that occurs during replication.  Helicase separates the lagging and 
leading strands as it propels itself forward along the strand.  Single-strand DNA-binding 
(SSB) proteins bind to the single-stranded DNA directly behind the helicase, preventing 
the duplex from reforming.  The SSB proteins bind without interfering with subsequent 
protein interactions.  DNA polymerase polymerizes nucleotides in the 5’ to 3’ direction, 
using free mononucleotides as substrates for the leading strand, by addition of the 5’ end 
of the nucleotide phosphate to the 3’-OH end of the deoxyribose. DNA primase 
introduces an RNA based primer on the lagging strand.  DNA polymerase is then able to 
create Okazaki fragments in a 5’ to 3’ direction.  Exonuclease, not pictured, removes the 
RNA primer.  Additional Okazaki fragments are then formed further upstream.  The 5’ 
end of the former fragment is then joined with the 3’-OH of the newer fragment by DNA 
ligase.  Through this semiconservative process, two new daughter strands are formed 




Figure 1.3 Model of the transcription of DNA into messenger RNA (mRNA).   
Reused from Clancy, S., DNA transcription. Nature Education 2008, 1 (1:41) with 
permission (14).  
A) Transcription factors bind to promoter regions upstream of the target DNA.  RNA 
polymerase then binds at the initiation site of the template strand. B) RNA polymerase 
forms a transcription bubble by cleaving the hydrogen bonds which bind the two strands 
to each other. RNA polymerase proceeds down the DNA template strand in a 3’ to 5’ 
manner, matching ribonucleotides to the template strand and forming an RNA transcript 
strand in a 5’ to 3’ manner which matches the coding DNA strand complementary to the 
template strand. C) mRNA elongation ends when the polymerase extends to the 
termination site and the mRNA is separated from the template strand (14) 
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1.3 B DNA 
DNA has several distinct conformations within the nucleus. However, for the bulk 
of therapies, double helical B-DNA provides several distinct possibilities as a target (15-
17).   Major grooves (22 Å wide) and minor grooves (12 Å wide) found in the phosphate 
backbone of DNA offer binding specificity, a feature that is exploited in DNA-protein 
binding (18).  This specificity arises not only from steric constraints, but also from 
hydrogen bond acceptor and donor positioning among other intermolecular interactions, 
including π-stacking, halogen bonding, and cation-π interactions.  The specific thymine-
adenine and cytosine-guanine binding offers distinct differences in binding environments, 
as shown in Figure 1.4 (19). 
 
 
Figure 1.4 Diagram of the Watson-Crick base pairing of thymine with adenine and 
cytosine with guanine 
Distinct functional environments are present in the major and minor grooves.  The major 
groove displays a hydrogen bond acceptor at the O4 of thymine, donor at adenine N6 and 
acceptor at adenine N7.  The minor groove exhibits a hydrogen bond acceptor at thymine 
O2 and adenine N3.  This positioning of hydrogen bond acceptors and donors allows for 




1.3.1 Alkylating agents 
The first group of DNA targeting therapies in the modern era consisted of 
nitrogen mustards (12).  These covalently modify DNA, offering inhibition of DNA 
processes and ultimately leading to cellular death. Their primary mechanism of action is 
alkylation of the N7 of guanine (5).  This nitrogen is nucleophilic and able to react with 
the electron deficient carbon(s) of the mustard (5, 12).  Further “generations” of 
alkylating/covalently modifying agents have involved transition metals, e.g. platinum in 
Cisplatin, a frontline cancer treatment.  Cisplatin causes 1,2-intrastrand d(GpG) linkages 
through covalent modification of the N7 of guanine as the primary product, as shown in 
Figure 1.5 (20).  The drawback of the majority of alkylating agents is their nonspecificity 
in targeting.  Because of this, patients experience a myriad of side effects and even refuse 
treatment due to the negative effects of the drugs (21). 
1.3.2 Minor groove binding agents 
Advances in therapies have arisen through drugs that have sequence specificities 
or act solely on DNA (platins, mustards, and other alkylating agents are non-specific to 
DNA and are able to alkylate proteins and other intracellular and extracellular molecules) 
(5).  Further research has evolved into numerous accounts of minor groove binding 
agents dependent on non-covalent interactions (5, 12, 19, 22-24).  A large majority of 
these agents exhibit a characteristic “crescent shape” believed to enhance their ability to 
lie within the minor groove of DNA (5).  In addition to the crescent shape, most minor 
groove binders are characterized by the presence hydrogen bond donors and acceptors, in 
addition to some amount of positive charge.  The positive charge allows for favorable 




Figure 1.5 Crystal structure of the binding of cisplatin to DNA through the N7 
position of adjacent guanines (1,2-intrastrand linkage).  
Adapted with permission from Todd et al. (20). 
 
Brostallicin, a polyamide, crescent shaped minor groove specific alkylating agent, 
shows specificity to 5’-AAAG-3’ and alkylates the N3 of adenine. Brostallicin has an 
appreciable therapeutic index with an ED50 of 0.6-2 nM (as low as 0.46 nM in a cell line 
known for a high level of glutathione, a reducing agent commonly seen in hypoxic 
tumors). The binding affinity of Brostallicin for the minor groove of B-DNA arises from 
the hydrogen bond donating and accepting ability of secondary amides (hydrogen bond 
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donation from the amide proton and hydrogen bond accepting ability through a lone pair 
on the amide carbonyl oxygen) (15).  Numerous studies have been performed on 
distamycin and related pyrrole polyamide crescent shaped minor grove binders that do 
not covalently modify DNA as Brostallicin does (5, 12, 19, 24, 25) 
Thiazotropsin B, shown in Figure 1.6a is one such polyamide minor groove-
binding drug. The polyamide skeleton gives crescent shape conformational ability as well 
as hydrogen bond acceptors and donors (16).  Thiazotropsin B stabilizes dACGCGT to a 
greater extent than dACTAGT. Substitution of a pyrrole with imidazole and 
transformation of the aldehyde to a methyl ketone yields Thiazotropsin A, which has the 
reverse affinity for the two nucleotides (16, 19).  This yields additional credence to the 
role of functional groups in base pair specificity. Additionally, Thiazotropsin B binding 
to DNA has a stoichiometry of 2:1 and binds in a “head to tail” directionality, as shown 
in Figure 1.6b. This is due to functional group association compatibility within the dimer 
formed from two Thiazotropsin B units. This binding mode increases the width of the 
minor groove. This binding driven widening of the minor groove compacts the major 
groove and offers allosteric inhibition of the binding of DNA binding proteins to the 
DNA major groove in this sequence, offering the potential of chemotherapeutic ability 





Figure 1.6 A) Structure of Thiazotropsin B. B) Cartoon of the solution structure for 
the 2:1 complex of Thiazotropsin B with d(CGACGCGTCG)2.  B) was 
reproduced with permission from Alniss et al. (2).  
The two Thiazotropsin B ligands are self-associated as a dimer in a head to tail manner 
within the minor groove of the duplex.  The presence of the ligand dimer causes 
substantial distortion of the duplex through widening of the minor groove and subsequent 
compaction and deepening of the major groove, which would allow for allosteric 
inhibition of protein binding to the major groove (2). 
1.3.3 B-DNA intercalative agents 
In addition to minor groove electrostatic interactions, molecules are able to 
intercalate between base pairs in several types of DNA, including B-form duplex DNA. 
The intercalation of molecules is due mostly to favorable π-π interactions. A planar, 
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conjugated molecule is able to insert into base pairs and exhibit π-orbital overlap with the 
planar, conjugated base pairs (12, 22). 
Doxorubicin (Figure 1.7), another frontline drug, acts through this intercalative 
mode by selectively intercalating between cytosine and guanine, as shown in Figure 1.8 
(22, 26).  It also offers additional stabilization through hydrogen bonding from its amino 
sugar group to flanking base pairs, bonding to a cytosine deoxyribose and a thymine 
carbonyl. Binding to d(CGATCG) is tighter than that of d(CGTACG), where the thymine 
and adenine have been swapped. This specificity is believed to be due to the presence of 
the amino-sugar, and crystal structures support this hypothesis (22).  Subtle differences in 
DNA configuration and ligand functional groups can have drastic changes in the binding 
ability of ligands; however, a major downfall to doxorubicin therapy is cardiomyopathy, 
which may arise due to the oxidative stress caused by the incomplete specificity in the 
action of doxorubicin (27, 28). 
 





Figure 1.8 Crystal structure of the binding mode of doxorubicin with duplex DNA. 
Adapted with permission from Frederick, C. A.; Williams, L. D.; Ughetto, G.; Van der 
Marel, G. A.; Van Boom, J. H.; Rich, A.; Wang, A. H. J., Structural comparison of 
anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 1990, 29 
(10), 2538-2549. 1990. American Chemical Society. 
Association proceeds through intercalation between cytosine and guanine residues with 
additional stabilization from hydrogen bonding between the doxorubicin amino sugar and 
cytosine and thymine heteroatom.  
1.4 G-quadruplex DNA 
 The G-quadruplex is a non-canonical four stranded DNA construct capable of 
forming from DNA sequences with high frequencies of guanine.  G-quadruplexes offer 
an attractive therapeutic target as there are roughly 3.7 million guanine rich sequences 
within the human genome.  These sequences occur in numerous areas including the c-
MYC, BCL-2, KRAS, c-KIT, and VEGF oncogene promoter regions as well as the 3’ 
overhang of DNA, the telomere (29). 
The first report of guanine-guanine based associations was published by Ivar 
Bang in 1910 in which it was reported that millimolar concentrations of guanylic acid 
formed a gel (30).  Further investigations demonstrated that self-assembly of guanylic 
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acids into tetrameric units able to form a helical structure was responsible for the gel-like 
properties (31).  The link between guanylic acid gels and the formation of G-quadruplex 
structures from DNA was not made until Henderson et al. observed that guanine rich 
telomeric sequence oligonucleotides exhibited abnormally high stability under denaturing 
conditions (32).  Since then, numerous investigations have shown through the use of G-
quadruplex specific binding antibodies, as well as spectroscopic investigations, have 
shown that G-quadruplexes are able to form in vitro and are likely able to form in vivo, 
and are therefore a physiologically relevant target in drug therapies (29, 33-37). 
G-quadruplexes are formed through non-Watson-Crick guanine-guanine based 
association. Hoogsteen hydrogen bonding among four separate guanine residues can form 
a square planar structure, a G-tetrad, shown in figure 1.9a (38).  These tetrads are then 
able to self-assemble and stack through π-π stacking to form a G-quadruplex depending 
on the number of contiguous guanines within a sequence, as shown in Figure 1.9b.  
Monovalent cations present in the channel formed among the bases of the G-quadruplex 
offer additional stabilization and are often, at least in biologically relevant systems, 




Figure 1.9 A) Chemical diagram of a G-tetrad. B) Simplistic cartoon of a G-
quadruplex. 
Hoogsteen hydrogen bonding among four guanine residues forms a square planar G-
tetrad.  G-tetrads are then able to form a G-quadruplex through π-π stacking.  The 
presence of a monovalent metal ion in the central channel offers additional stabilization 
(39).  
1.4.1 Quadruplex conformations and structural stability 
G-quadruplex DNA is able to adapt a number of sequence orientations including 
parallel, antiparallel, and mixed conformations, as illustrated in figure 1.10 (38).  
Intramolecular and intermolecular G-quadruplexes can be formed, including 
unimolecular, bimolecular and tetramolecular structures.  In general, G-quadruplexes 
formed in potassium solutions tend to favor a parallel conformation while G-
quadruplexes formed in sodium solutions tend to form antiparallel G-quadruplexes, but 
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this is by no means the rule (40-42).  The polymorphism of G-quadruplex structures in 
evident in that fact that in addition to the general trends, parallel G-quadruplexes may be 
seen in sodium solutions with antiparallel G-quadruplexes present in potassium solution.  
Structural stability also varies as it is dependent upon not only the presence and 
identity of the cation present within the channel, but also on the number of nucleotides on 
both the 5’ and 3’ side of the structure as well as the number and composition of the 
nucleotides forming the loops within the complex.  Higher concentrations of the 
supporting electrolyte help to stabilize the structure to a greater extent than lower 
concentrations.  Dettler et al. reported that the first and second melting temperature for a 
24 nucleotide long oligonucleotide c-MYC WT 24 mer (5’-
TGGGGAGGGTGGGGAGGGTGGGGA-3’) were 71.0 °C and 80.1 °C respectively in 
30 mM K+ and 78.8 °C and 93.1 °C respectively in 130 mM K+ (44).  Conversely, Blume 
et al. and other groups have reported that the presence of divalent cations causes a 
decrease in structural stability, even in the presence of potassium ions (45, 46). 
1.4.2 Quadruplex binding ligands 
G-quadruplexes may also be stabilized or destabilized by the presence of one or 
more bound small molecules that generally exhibit some type of conjugated or aromatic, 
planar core that is able to non-covalently bind to the G-quadruplex through π-π stacking.  
In addition to the conjugated or aromatic, planar core, a number of G-quadruplex binding 
small molecules also exhibit some degrees of cationic charge that is able to offer 
additional binding stability through ionic interactions with the negatively charged 





Figure 1.10 Diagram of the conformational heterogeneity possible with G-quadruplex 
structures. Reproduced from Phan et al. with permission (43).   
The red lines in the figures represent the loops, cyan squares are syn- guanine residues 
and magenta colored squares are anti- oriented guanine residues. A) Figure for the 
conformation of residues 2 through 22 for d[AGGG(TTAGGG)3] (hTel22) in Na+ 
solution. B) Figure for the conformation of residues 2 through 22 for htel22 in K+ crystal. 
C) Figure for the conformation of residues 3 through 23 for d[TAGGG(TTAGGG)3] in K 
solution.  D) Figure for the conformation of residues 3 through 23 for 
d[TAGGG(TTAGGG)3TT] in K+ solution (43).  
Telomestatin (Figure 1.11a), a macrocycle first isolated from Streptomyces 
anulatus, inhibits the ability of telomerase to extend the TTAGGG telomeric repeat with 
an IC50 of 5 nM without interfering with DNA polymerase activity.  The proposed 
mechanism of inhibition proceeds through the induction or stabilization of a basket type 
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antiparallel G-quadruplex with a 2:1 binding stoichiometry (2 equivalents of telomestatin 
to 1 equivalent of a 3 tetrad G-quadruplex) (48, 49).  Diseleno sapphyrin (Figure 1.11c) 
binds to G-quadruplex DNA with a 1:1 stoichiometry and was found to convert 
preformed a preformed antiparallel basket type G-quadruplex to a hybrid, mixed 
parallel/antiparallel G-quadruplex (49).  Braco-19 (Figure 1.11d), an aminoacridine based 
selective telomerase inhibitor, has been shown to cause growth inhibition in tumor cell 
lines as well as p21 and p53 mediated apoptosis (50). 
TMPyP4 (Figure 1.11b), while not a serious drug candidate, has been extensively 
studied as a model G-quadruplex binding molecule and is the basis for many G-
quadruplex binding studies.  Han et al. found that binding of the cationic porphyrin 
proceeds via an n+1 stoichiometry, where n is the number of tetrads present in a G-
quadruplex (51).  For a G-quadruplex containing three tetrads, the binding stoichiometry 
was found to be 4:1 (4 equivalents of TMPyP4 to 1 equivalent of a 3 tetrad G-
quadruplex) and to proceed through two distinct binding modes.  The first binding mode 
is driven by a favorable enthalpy change and proposed to be end-stacking, whereas the 
second mode is entropically driven and proposed to proceed through intercalation of the 
porphyrin between the tetrads of the G-quadruplex (52).  Binding of TMPyP4 to a G-
quadruplex forming sequence shifts the equilibrium between duplex and G-quadruplex 
formation for the binding of the G-quadruplex forming sequence to its complementary 
strand towards that of the G-quadruplex, effectively lowering the affinity of the G-
quadruplex forming sequence for that of its complementary mate by 30% and slowing the 




Figure 1.11 Chemical structures for the G-quadruplex interacting compounds: A) 
Telomestatin B) TMPyP4 C) Diseleno sapphyrin (Se2SAP) D) Braco-19. 
These G-quadruplex binding agents exhibit the general planar conjugated or aromatic 
core necessary for π-π stacking with the guanine residues of the quadruplex.  Additionally 
TMPyP4, Se2SAP, and Braco-19 display additional cationic charges that are able to offer 
additional binding stability through ionic interaction with the DNA’s negatively charged 
phosphate backbone (47-53). 
 
1.4.3 The implications of the interactions of G-quadruplex binding ligands with 
G-rich oncogenes 
1.4.3.1 c-MYC NHE-III1  G-quadruplex studies 
The c-MYC proto-oncogene promoter c-MYC nuclease hypersensitivity element 
III1 (c-MYC NHE III1, Figure 1.12) is responsible for 80-90% of all c-MYC transcription 
(54).  It is composed of a guanine (and complementary cytosine) rich sequence capable of 
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forming G-quadruplex (and complementary I-motif) structures located -142 to -145 base 
pairs upstream of the P1 promoter and has been proposed as a chemotherapeutic target 
due to the overexpression of c-MYC in a variety of human cancer types including breast, 
colon, and ovarian cancers (55).  The overexpression of c-MYC in malignant cells is 
precarious due to its role in regulating up to 15% of all gene expression (56).  In the 
presence of c-MYC, genes already upregulated in tumor cells are amplified to a greater 
extent than gene with normal or low levels of expression (57). 
The G-quadruplex forming ability of the c-MYC NHE III1, region and its 
interactions with binding agents such as cationic porphyrins, has been investigated as a 
means by which to control c-MYC expression (44, 58-61).  In fact TMPyP4 is able to 
suppress c-MYC transcription when the NHE-III1 region is present, allowing it to act as a 
transcription silencing element.  When the gene sequences lack the element, TMPyP4 
does not suppress transcription, suggesting that G-quadruplex stabilizing compounds 
could potentially be effective chemotherapeutic agents (62). 
 Binding of TMPyP4 to a model c-MYC sequence (5’-
GGGGAGGGTGGGGAGGGTGGGGAAGG-3’) proceeds through two distinct binding 
modes, the first with an affinity of 5.4 *106 M-1 and the second with an affinity of 2.0 
*105 M-1, as measured with isothermal titration calorimetry (ITC).  Much like the 
TMPyP4 binding events discussed earlier, the stronger binding event is driven by a 
favorable change in entropy followed by a weaker event dependent on a favorable change 
in enthalpy and a binding stoichiometry of 2:1 for the first mode and 2:1 for the second 
mode.  Titration experiments under varying salt concentrations show that as the 




Figure 1.12 Cartoon diagram showing the route of c-MYC transcription silencing by G-
quadruplex stabilizing compounds. Reproduced from Brooks et al. with 
permission (54). 
A) The transcriptionally inactive form of the c-MYC NHE III1 oncogene promoter region 
contains guanine and cytosine rich sequences which can form both G-quadruplex and I-
motif structures, respectively. B) Resolution of the higher ordered DNA structures (G-
quadruplex and I-Motif) by NM23-H2 allows c-MYC to transform into the 
transcriptionally active form.  C) The transcriptionally active form allows for the binding 
of transcription factors to begin c-MYC transcription. D) A quadruplex binding protein 
such as nucleolin (shown in orange) is able to lock c-MYC NHE III1 into the 
transcriptionally inactive form by binding to the G-quadruplex.  E) G-quadruplex 
interactive compounds such as TMPyP4 can stabilize the c-MYC NHE III1 G-quadruplex, 
also locking the promoter sequence in the transcriptionally inactive form (54).  
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1.4.3.2 BCL-2 G-quadruplex studies 
B-cell lymphoma 2 (BCL-2) is an antiapoptotic protein coded for by the BCL-2 
oncogene.  Due to the overexpression of BCL-2 in number of cancers, malignant cells are 
less likely to undergo apoptosis in these cancers with upregulated antiapoptotic factors.  
This allows them to remain in a G0 state until upregulated oncogenes, such as c-MYC, 
provide the necessary transcription factors to being replication (63).  This BCL-2 
upregulation has been proposed as a mechanism for the treatment resistance that often 
arises during treatment in certain cancer types.  The presence of a G-quadruplex forming 
sequence in the promoter region, much like c-MYC, offers a potential chemotherapeutic 
target for the downregulation of BCL-2 compounds are able to interact with and stabilize 
the G-quadruplex (39).  
Nagesh et al. has shown that TMPyP4 is able to interact with the BCL-2 promoter 
sequence G-quadruplex (5’-CGGGCGGGGGAGGAAGGGGGCGGGAGC-3’) through 
two distinct modes.  Mode I exhibits a binding affinity of 4.2 * 107 M-1 and is driven by a 
favorable change in entropy, suggesting end stacking, while mode II proceeds with an 
affinity of 3.6 *105 M-1 and is characterized by a favorable change in enthalpy, 
suggesting intercalation.   
Planarity of the cationic porphyrin is necessary for optimum binding as reported 
by Le et al. It was found that the sterically induced non-planarity of the methyl 
pyridinium groups in TMPyP2 (Figure 1.13a) and TMPyP3 (Figure 1.13b) decreased the 
binding affinity of the porphyrin/G-quadruplex complex with respect to the planar 
TMPyP4.  Additionally, the second binding mode of TMPyP4 (Figure 1.13c) type 
association was not seen in the TMPyP2 and TMPyP3 experiments (52).  The single 
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binding mode seen for TMPyP3 and TMPyP2 associated proceeded through an 
entropically driven binding process, suggesting that the non-planarity of the ligands 
inhibits an intercalative binding mechanism (52, 64, 65). 
 
Figure 1.13 A) Chemical structure of TMPyP2. B) Chemical structure of TMPyP3. C) 
Chemical structure of TMPyP4. 
 
1.5 Outline of this work 
The work presented in this dissertation involved studying the binding of model 
DNA binding small molecules (ligands) with DNA constructs to further understand how 
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structural perturbations in model ligands affect the thermodynamics of the binding 
process.  The thermodynamic studies presented in this dissertation primarily use 
isothermal titration calorimetry to analyze binding reactions to determine the full set of 
thermodynamic parameters associated with those reactions.  Supplemental analytical 
techniques include UV-Vis and circular dichroism spectroscopies.   
In Chapter 2, structural changes of a pyridinium substituted porphyrin core were 
investigated to determine charge, size, shape, and symmetry affect the thermodynamic 
parameters associated with the molecular recognition of planar aromatic molecules for G-
quadruplex structures.  This was performed by modulating the number or pyridinium 
groups on the porphyrin core. Cationic porphyrins of higher symmetry (TMPyP4 and A2 
trans) exhibited higher binding affinities against a model BCL sequence G-quadruplex 
when compared with porphyrins of lower symmetry (A3 tris, A2 cis, and A1 mono).  
Chapter 3 builds upon the study in Chapter 2 by investigating how substitution of 
metals into the porphyrin core would affect binding.  Porphyrins containing Cu2+ and Ni2+ 
metal centers, with no or only weakly bound axial ligands, bound to a model human 
telomeric G-quadruplex with affinities equal to or greater than the unmetallated 
porphyrin, whereas the porphyrins containing Co3+ and Zn2+, with one or two strongly 
bound axial ligands, exhibited markedly decreased binding affinities and lower saturation 
stoichiometries.  
 In Chapter 4, a series of cationic ruthenium containing polyheterocyclic 
molecules starting with a positively charged minor groove binder and leading to 
molecules with a greater intercalative abililty were investigated for their binding 
properties with B-DNA.  It was found that [Ru(phen)2t(tatpp)]2+ exhibited a higher 
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binding affinity than [(phen)2Ru(tatpp)Ru(phen)2]2+ for a model duplex, a likely source 
for the better IC50 exhibited by [Ru(phen)2t(tatpp)]2+. 
These studies have been successful in part in determining the contributions of 
numerous weak interactions on the binding of ligands to model DNA constructs.  The 
binding of porphyrins to G-quadruplex DNA was found to be greatly affected by charge, 
hydrophobic interactions, shape, symmetry, and solvent structure.  Ruthenium(II) 
compounds were found to bind more tightly as the length of the intercalator increased 
(dependent on size, solvent accessible surface area, and π-bonding), but the additional 
charge of the second ruthenium center in the binuclear complexes actually caused a 
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THE EFFECT OF PYRIDYL SUBSTITUENTS ON TH ETHERMODYNAMICS OF 
PORPHYRIN BINDING TO G-QUADRUPLEX DNA 
Previously published in Bioorganic & Medicinal Chemistry 2013, 21, 7515-7522 
and reproduced with permission. 
2.1 Abstract 
Most of the G-quadruplex interactive molecules reported to date contain extended 
aromatic flat ring systems and are believed to bind principally by π-π stacking on the end 
G-tetrads of the quadruplex structure. One such molecule, TMPyP4, (5,10,15,20-tetra(N-
methyl-4-pyridyl)porphyrin), exhibits high affinity and some selectivity for G- 
quadruplex DNA over duplex DNA.  Although not a realistic drug candidate, TMPyP4 is 
used in many nucleic acid research laboratories as a model ligand for the study of small 
molecule G-quadruplex interactions.  This work reports on the synthesis and G-
quadruplex interactions of four new cationic porphyrin ligands having only 1, 2, or 3 (N-
methyl-4- pyridyl) substituents. The four new ligands are: P(5) (5-(N-methyl-4-
pyridyl)porphyrin), P(5,10) (5,10-di(N-methyl-4-pyridyl)porphyrin), P(5,15) (5,15-di(N-
methyl-4-pyridyl)porphyrin), and P(5,10,15) (5,10,15-tri(N-methyl-4-pyridyl)porphyrin). 
Even though these compounds have been previously synthesized, alternative synthetic 
routes that are more efficient and that result in higher yields were utilized.  ITC, CD, and 
ESI-MS were used to explore the effects of the number of N-methyl-4-pyridyl 
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substituents and the substituent position on the porphyrin on the G-quadruplex binding 
energetics. The relative affinities for binding these ligands to the WT Bcl-2 promoter 
sequence G-quadruplex are: KTMPyP4 ≈ KP(5,15) > KP(5,10,15) >>> KP(5,10), KP(5).  The 
saturation stoichiometry is 2:1 for both P(5,15) and P(5,10,15), while neither P(5) nor 
P(5,10) exhibit significant complex formation with the WT Bcl-2 promoter sequence G- 
quadruplex.  Additionally, binding of P(5,15) appears to interact by an “intercalation 
mode” while P(5,10,15) appears to interact by an “end-stacking mode”. 
2.2 Introduction 
Over expression of BCL-2 has been observed in a number of cancers including: 
breast, prostate, cervical, colorectal, and lung carcinoma (1). The human BCL-2 P1 
promoter region is GC-rich and the G-rich strand is known to form a stable G-
quadruplex structure (2).  The stabilization of oncogene promoter sequence G-
quadruplexes and telomere overhang repeat sequence G-quadruplexes by binding small 
molecules (e.g. ligands or drugs) is a subject of interest in cancer drug discovery. 
Ligands exhibiting structural recognition (selectivity) and high affinity for G-quadruplex 
DNA including several porphyrin based compounds have been explored for their 
potential as anti-cancer drugs (3-6). The porphyrin-based ligands have shown the ability 
to inhibit telomerase and they typically exhibit low cytotoxicity (5, 6).  TMPyP4, 
(5,10,15,20-tetra(N-methyl-4-pyridyl)porphyrin), while not a serious drug candidate, 
has been used extensively as a model ligand in the characterization of the structure, 




The Lewis group has published several studies on the interactions of TMPyP4 
with several oncogene promoter sequence G-quadruplexes including c-MYC, BCL-2, and 
K-ras (7-11). The Lewis group has also shown that that TMPyP4 binding to these G-
quadruplexes results in a complex having 4 moles of TMPyP4 per mole of quadruplex 
and that the complex is stabilized significantly over the naked G-quadruplex. TMPyP4 
binds to these G-quadruplexes by two distinctly different binding modes, a higher affinity 
mode which is driven by a favorable entropy change and a weaker mode which is 
accompanied by an unfavorable entropy change. We believe that these two modes 
represent first the end-binding of two moles of TMPyP4 followed by the intercalation of 
another two moles of TMPyP4 so that every G-tetrad is sandwiched between two planar 
porphyrin molecules. Le et al. recently reported on a study of the interactions of three 
related porphyrins, (TMPyP2, TMPyP3, and TMPyP4), with a WT 39-mer Bcl-2 
promoter sequence G-quadruplex (7).  Using CD, Fluorescence, ITC, and ESI-MS, it was 
shown that as the substituted porphyrin becomes non-planar, the intercalation binding 
mode is eliminated so that the saturation stoichiometry for binding TMPyP2 or TMPyP3 
becomes 2:1 (15).  In addition, the end-stacking mode is also weakened as the porphyrin 
ligand becomes increasingly less planar with the binding of TMPyP2 << TMPyP3.  
TMPyP4 like many other G- quadruplex interactive ligands reported to date are planar 
heterocyclic aromatic ring systems (16-25).  The porphyrin ligand charge (e.g. +1, +2, 
+3, or +4), size (e.g. SASA (solvent accessible surface area)), shape (e.g. planarity) and 
symmetry (e.g. substitution pattern) may all play a role in establishing the selectivity and 
affinity for G-quadruplex complex formation.  This study has begun to explore each of 
these effects by synthesizing new ligands that are systematically reduced in size, charge, 
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and symmetry in comparison to TMPyP4.  The new ligands differ from the model 
TMPyP4 quadruplex interactive compound by having only one, two, or three (N-methyl-
4-pyridyl) substituents.  
ITC, CD, and ESI-MS were used to study the interactions of these new porphyrin 
ligands with a 27-mer WT BCL-2 P1 promoter sequence G-quadruplex. Although 
Goncalves et al. has already reported the synthesis for the P(5) (5-(N-methyl-4- 
pyridyl)porphyrin), P(5,10) (5,10-di(N-methyl-4-pyridyl)porphyrin), P(5,15) (5,15-
di(N-methyl-4-pyridyl)porphyrin), and P(5,10,15) (5,10,15-tri(N-methyl-4-
pyridyl)porphyrin) compounds (26), this work presents alternative synthetic routes that 
are more efficient and that result in higher yields. Goncalves et al. also reported SPR 
experiments from which they estimated the binding affinities for these same four ligands 
with a human telomere repeat sequence G-quadruplex (26).  In these experiments, the G-
quadruplex is different, but even more importantly, the complete set of thermodynamic 
parameters for the formation of these four porphyrin ligand complexes with a typical 
oncogene promoter sequence G-quadruplex have been determined. The ITC, CD, and 
ESI-MS data reported here have been analyzed to yield values for the free energy 
changes (ΔG), the enthalpy changes (ΔH), the entropy changes (-TΔS), and the saturation 
stoichiometry (n) for the formation of the WT BCL-2 27-mer P1 promoter sequence G-
quadruplex complexes with P(5), P(5,10), P(5, 15) and P(5,10,15). 
2.3 Materials and Methods 
2.3.1 Binding studies 
The WT 27-mer BCL-2 oligonucleotide used in this study was obtained from 
Midland Oligos (Midland, TX).   The oligonucleotide has the following sequence 5’- 
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CGG GCG CGG GAG GAA GGG GGC GGG AGC -3’. DNA stock solution was 
prepared by reconstituting the lyophilized oligonucleotide into KBPES buffer with a salt 
concentration of 130 mM [KCl] and a pH of 7.0.  Approximately 2 mL of the 
oligonucleotide was dialyzed (1000 MW cutoff membrane) against three changes of 
buffer solution (1 L, 24 h each) at 4 °C. The concentrations of stock DNA solution were 
verified using UV-Vis.  DNA was annealed by quickly heating the sample to 100 °C, 
holding at 100 °C for ten minutes then slowly cooling to 5 °C over a three hour period. 
The molar extinction coefficient of the DNA was determined using a nearest-neighbor 
method for single stranded DNA (27).  The extinction coefficient at 260 nm for the WT 
27-mer Bcl-2 sequence was: 2.26×105 M-1 cm-1. 
CD experiments were performed with an Olis DSM-20 spectropolarimeter 
(Bogart, GA).  All measurements were done at 25 °C using a 1 cm quartz cuvette and 
covering a spectral range of 225-325 nm. All CD samples were prepared such that they 
had a nominal absorbance of less than 1.0 at 260 nm. 
ITC experiments were performed using a VP-ITC calorimeter (GE-Healthcare). 
A typical ITC experiment involved the addition of 28 (10 μL) injections of a dilute (115 
μM) WT 27-mer Bcl-2 DNA solution into ~ 1.5 mL of a dilute porphyrin solution (5 μM).  
Reverse titrations were employed because of the low solubility of the substituted 
porphyrins.  Three replicate experiments were done for each of the four porphyrins. Blank 
titrations were done by injecting the titrant (115 μM G-quadruplex) into buffer solution. 
Corrected titration curves were achieved by subtracting the blank titration data from the 
ITC data for the porphyrin-DNA titrations. Corrected ITC titrations were fit with a 
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nonlinear regression algorithm again using the CHASM© ITC data analysis program 
developed in the Lewis laboratory (28). 
ESI-MS experiments on BCL-2 and the BCL-2 porphyrin complexes were carried 
out on a Bruker MicrOTOFQ mass spectrometer. Data acquisition was set to operate in 
negative ion mode. All experiments were performed in 50 mM ammonium acetate buffer 
(pH = 7.0) containing 20% HPLC grade methanol. The WT Bcl-2 27-mer G-quadruplex 
sample was prepared at a concentration of approximately 25 μM in the ammonium acetate 
buffer and was dialyzed against three changes of buffer 12 hours each at 4 °C.  Stock 
solutions of the porphyrin ligands were prepared in the final dialysate buffer at 
concentration as high as 50 μM.  The ESI-MS samples were prepared by mixing the DNA 
and ligand stock solutions to yield a mixture containing 4 equivalents of each porphyrin 
ligand per equivalent of DNA. The MS capillary voltage was set to +3500 V, dry N2 gas 
flow was adjusted to 0.5 L/min at 110°C, and the G-quadruplex/porphyrin samples were 
directly infused into the MS by using a kD Scientific syringe pump set to a flow rate of 
200 µL/hour. Data processing was performed by using Bruker Daltonics Data Analysis 
program. 
2.3.2 Porphyrin ligand synthesis 
The overall synthesis for the four porphyrin ligands studied here is shown in 
Scheme 2.1.  The synthesis of the substituted porphyrins began by synthesizing the key 
dipyrromethane building blocks 1 and 4 by condensation of the respective aldehydes 
with pyrrole (29, 30).  Formylation of 1 utilizing a Vilsmeier reaction gave compound 2 
in 45% yield (26).  Functionalized dipyrromethane 5 was synthesized by the 
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diformylation of pyridyl dipyrromethane 4 also utilizing a Vilsmeier reaction in 28% 
yield (26).  The reduction of formylated dipyrromethane 5 with sodium borohydride 
provided compound 6, which was used in subsequent steps without purification (26).  
 With the key building blocks in hand, the synthesis was directed to the desired 
porphyrin analogues. The synthesis of P(5) was accomplished by the condensation of 
dipyrromethanes 1 and 6 in the presence of trifluoroacetic acid. The resulting mixture 
was allowed to stir for one hour, oxidized with DDQ, and treated with triethylamine to 
provide porphyrin 7 in 8% yield. Methylation of 7 with iodomethane followed by 
washing with ether provided P(5) in 16% yield (26). 
The synthesis of P(5,10) was accomplished by deprotonation of compound 6 
with ethyl magnesium bromide followed by the addition of Mukiyama reagent 8 resulted 
in the formation of compound 9 in 41% yield (31). The condensation of compounds 2 
and 9 resulted in the formation of porphyrin 10 in 35% yield (32).  Methylation of 14 
provided the P(5,10) in 6% yield (26). 
Porphyrin P(5,15) was synthesized by the condensation of compound 4 with 
trimethyl orthoformate 11 followed by methylation provided P(5,15) in 2% overall yield. 
Condensation of compounds 3, 4, and 11 followed by methylation resulted in the 




Scheme 2.1 Synthetic routes for the four cationic porphyrin ligands used in this study 
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2.3.2.1 Dipyrromethane 1 (30): 
Paraformaldehyde (1.73g, 57.7mmol) and pyrrole (100mL, 1.44 mol) were added 
to a 250mL two-necked round-bottom flask equipped with a condenser and an internal 
thermometer. The mixture was brought to an internal temperature of 65 °C. The flask was 
removed from the heat and TFA (444 μL, 5.77 mmol) was added. The mixture was 
purified via flash chromatography eluting at 8-10% EtOAc in hexanes affording 3.17g of 
1 as a white solid in 37% yield. 1H NMR (300MHz, DMSO-d6): δ = 3.807 (s, 2H), 5.744 
(s, 2H), 5.884-5.893 (d, 2H), 6.583 (s, 2H), 10.502 (br s, 2H). 
2.3.2.2 1-formyl dipyrromethane 2 (26): 
DMF (24.2 mmol, 1.9 mL) was added to a dry RBF and cooled to 0 °C. POCl3 
(0.3 mL, 3.01 mmol) was added drop wise and stirred for 10 min to yield the Vilsmeier 
reagent. In another dry RBF, dipyrromethane 1 (0.500 g, 3.42 mmol) was dissolved in 
DMF (7.5 mL) under argon and cooled to 0 °C. To the reaction mixture, the freshly 
prepared Vilsmeier reagent (1.9 mL, 3.36 mmol,) was added drop wise and stirred at 0 °C 
for 2 h. After 2 h, a biphasic solution of ethyl acetate (50 mL) and saturated aqueous 
sodium acetate (50 mL) was added and stirred at room temperature for 4 h. Ethyl acetate 
was separated and the aqueous layer was extracted three times with ethyl acetate and the 
combined organic layer was washed with brine and water, dried over anhydrous Na2SO4 
and evaporated in vacuo to get crude product. The desired compound was isolated using 
automated flash chromatography, eluting at 20% EtOAc in DCM and evaporate in vacuo 
to yield 2 as a pale yellow solid (270 mg, 45.2%). 1HNMR (300 MHz, DMSO-d6): δ = 
11.93 (br s, 1H), 10.606 (br s, 1H), 9.328 (s, 1H), 6.867-6.887 (m, 1H), 6.602-6.607 (m, 
1H), 5.98-5.999 (m, 1H), 5.866-5.892 (m, 1H), 5.765 (br s, 1H), 3.868 (s, 2H) ppm. 
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2.3.2.3 5-(4-pyridyl) dipyrromethane 4 (29): 
4-pyridylcarboxaldehyde 3 (1.5mL, 16.4 mmol) and pyrrole (16mL, 230 mmol) 
were added to a microwave vial. The vial was sealed under argon and stirred for 20 min 
at 150 °C. The reaction mixture was cooled and concentrated under reduced pressure to 
yield a dark red liquid which was left on high vacuum overnight to yield a dark oil. The 
oil was dissolved in minimal DCM and wet-loaded onto a Biotage 50G column, packed 
with alumina oxide and purified via flash chromatography with DCM: EtOAc. Fractions 
containing product were collected and concentrated under vacuum. Minimal DCM was 
added to the resulting solid to create a slurry. Excess hexanes were added and the mixture 
was filtered, collecting 4 as a pale grey solid (645.1mg, 18.9% yield).  1 H NMR 
(300MHz, CDCl3): δ = 5.541 (s, 1H), 5.874 (s, 2H), 6.168-6.197 (q, 2H), 6.738-6.761 (q, 
2H), 7.313-7.340 (d, 2H), 7.599-7.627 (d, 2H), 7.973 (br s, 2H). 
2.3.2.4 1,9-Diformyl-5-(4-pyridyl)dipyrromethane 5 (26): 
The procedure of 1-formyldipyrromethane 2 was followed with DMF (6 mL, 58 
mmol), POCl3 (0.9 mL, 9.66 mmol) and replacing the dipyrromethane with 5-(4-pyridyl) 
dipyrromethane 4 (0.300 g, 1.34 mmol). The desired compound was isolated using 
automated flash chromatography, eluting at 9% MeOH in DCM and concentrated in 
vacuo to yield 5 as a brown oil (0.103 g, 28%). 1HNMR (300 MHz, CDCl3), δ = 10.96 (br 
s, 2H), 9.24 (s, 2H), 8.58 (d, J = 5.1 Hz, 2H), 7.28 (d, J = 5.1 Hz, 2H), 6.91 (s, 2H), 6.09 
(s, 2H) and 5.60 (s, 1H) ppm. 
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2.3.2.5 (5,5’-(pyridine-4-ylmethylene)bis(1H-Pyrrole-5,2-diyl)dimethanol  6 
(26): 
In a dry RBF under argon, 1,9-Diformyl-5-(4-pyridyl)dipyrromethane 5 (0.103 g, 
0.365 mmol) was dissolved in THF-Methanol (10:1, 20 mL) and cooled to 0 °C. NaBH4 
(0.29 g, 7.66 mmol) was added in roughly 50 mg portions every 2 min under a stream of 
argon. The reaction mixture was stirred at room temperature for 1 h and poured into a 
biphasic mixture of saturated aqueous ammonium chloride and DCM (1:1, 50 mL). The 
organic layer was washed with water twice and dried over anhydrous Na2SO4 and 
evaporated in vacuo to get crude 6 (100 mg) which was used directly in the next step. 
2.3.2.6 4-Pyridylporphyrin 7 (26): 
1 was added to the above 6 and stirred at room temperature for 5 min.  TFA 
(0.33 mL, 4.39 mmol) was added and the mixture was stirred for 1 h. DDQ (0.247 g, 
1.09 mmol) in toluene (6 mL) was added and stirred for1 h. Triethylamine (0.6 mL, 4.39 
mmol) was added and stirred for 10 min. The reaction mixture was evaporated in vacuo. 
Crude 7 was isolated at 2-10% MeOH in DCM as a purple solid (150 mg) using flash 
chromatography and purified by preparative TLC (eluted by 5% MeOH in DCM). The 
purple band was collected and extracted from the silica with MeOH. Evaporation of the 
solvent in vacuo gave 7 as a purple-red solid (6 mg, 8%). 1HNMR (600 MHz, DMSO-
d6): δ = 10.70 (s, 2H), 10.64 (s, 1H), 9.74-9.72 (m, J = 4.4 Hz, 6H), 9.33 (d, J = 5.9 Hz, 
2H), 9.27 (d, J = 4.4 Hz, 2H), 8.92 (d, J = 5.9 Hz, 2H) and -3.57 (br s, 2H, NH) ppm. 
2.3.2.7 S-2-Pyridyl isonicotinothioate 8 (31,32): 
An oven dried flask was charged with 2-mercaptopyridine (1.000 g, 8.99 mmol) 
and purged with argon. The solid was dissolved in anhydrous THF (20 mL) with stirring. 
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The solution was treated with isonicotinoyl chloride hydrochloride (1.600 g, 8.99 mmol). 
The resulting slurry was stirred overnight. The reaction mixture was filtered. The filtrate 
was washed with hexanes. The resulting orange solid was added to a biphasic solution of 
diethyl ether and saturated sodium bicarbonate and stirred until it no longer bubbled. The 
organic layer was collected and the aqueous layer was washed with diethyl ether (3 x 50 
mL). The organic layers were combined and dried with Na2SO4 and concentrated in 
vacuo to yield a yellow solid. Minimal THF was added to the solid to form a slurry which 
was filtered and washed with hexanes to yield 8 (0.8 g, 45%). 1HNMR (300 MHz, 
DMSO-d6): δ = 8.65 (m, 2H), 8.719 (m, 1H), 7.820-7.854 (m, 3H), 7.749 (d, J = 7.8 Hz, 
1H), 7.40 (m, 1H). 
2.3.2.8 1-Isonicotinoyl-5-(4-pyridyl) dipyrromethane 9 (31,32): 
To a solution of 6 (0.844 g, 3.8 mmol) in THF (15 mL) under argon was added 
dropwise 1.0 M EtMgBr (9.6 mL, 9.6 mmol) at room temperature. The flask was stirred 
for 10 min and cooled to -78 °C. S-2-pyridyl isonicotinothioate (0.795 g, 3.7 mmol)  in 
THF (15 mL) was added dropwise over 10 min and stirred for an additional 10 min 
before warming to RT and stirring for 4 h. The reaction was quenched at RT with 25 mL 
saturated aqueous NH4Cl. The slurry was extracted with EtOAc (3 x 25 mL). The 
organic layer was washed with DI water (3 x 20 mL), brine (3 x 20mL), dried with 
Na2SO4 and evaporated in vacuo to yield a yellow-brown solid. Flash chromatography 
gave 9 (0.506, 1.54 mmol) as a light brown solid in 41% yield eluting at 12% MeOH in 
DCM. 1HNMR (300 MHz, DMSO-d6): δ = 12.290 (br s, 1H), 10.809 (br s, 1H), 8.738 
(d, J = 4.8, 2H), 8.493 (d, J = 4.8), 7.650 (d, J = 4.8), 7.159 (d, J = 4.8, 2H), 6.774 (m, 
1H), 6.693 (m, 1H), 6.067 (m, 1H), 5.942 (m, 1H), 5.761 (m, 1H), 5.601 (s, 1H). 
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2.3.2.9  5,10-Di(4-pyridyl)porphyrin 10 (32): 
To a stirred solution of 1-formyldiprromethane 2 (0.018 g, 0.103 mmol) and 1- 
isonicotinoyl-5-(4-pyridyl) dipyrromethane 9 (0.035 g, 0.106 mmol) in 2.4 mL toluene 
in a microwave reactor vial was added DBU (0.35 ml, 2.3 mmol) and stirred for 10 min. 
MgBr2 (0.125 g, 0.67mmol) was added to the vial, which was then capped in atmosphere 
and heated to 115 °C for 90 min in the microwave reactor with magnetic stirring. The 
vial was emptied and rinsed with THF into a pear-shaped flask and evaporated. The 
crude solid was dissolved in DCM (15 mL) and washed with DI water (2 x 30 mL) and 
brine (2 x 30mL) dried with Na2SO4 and evaporated. The solid was dissolved in 4 mL 
DCM and demetallated with trifluoroacetic acid (0.050 mL) and neutralized with 
triethylamine (0.040 mL). After 5 min the mixture was washed with DI water (1 x 10 
mL) and brine (2 x 10 mL), dried with Na2SO4 and evaporated to dryness.  The crude 
product was then purified by column chromatography eluting at 45-50% MeOH in 
EtOAc. Evaporation of the solvent gave 10 (0.017g) in 35% yield. 1 HNMR (300 MHz, 
CDCl3): δ = 10.341 (s, 2H), 9.519 (s, 2H), 9.439 (m, 2H), 9.079 (m, 4H), 9.012 (m, 2H), 
8.936 (s, 2H), 8.206 (m, 4H), -3.422 (s, 2H). 
2.3.2.10 5,15-Di-(4-pyridyl)porphyrin 12 (26): 
5-(4-pyridyl) dipyrromethane 4 (1.000 g, 4.51 mmol), trimethyl orthoformate 11 
(36 mL, 329 mmol) and DCM (700 mL) were added to a flask covered with aluminum 
foil, stirred and degassed by bubbling with argon for 30 min. A solution of TCA (17.6 g, 
108 mmol) in DCM (300 mL) was added drop wise to the flask over 15 min. The 
reaction was stirred under argon for 4 h.  The mixture was quenched with pyridine (31.2 
mL) and stirred for 18 h. The reaction mixture was bubbled with air for 10 min. The 
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aluminum foil was removed and the reaction was stirred under ambient light for 4 h. The 
solvent was removed in vacuo to yield a black solid. The solid was filtered through a 
silica pad, and washed with DCM and 0.5% MeOH in DCM. The fraction collected was 
concentrated in vacuo and dissolved in DCM and filtered through a Buchner funnel to 
eliminate some black solid. The filtrate was concentrated to 3 mL and wet loaded onto a 
flash chromatography column. Automated flash chromatography gave pure fractions at 
1% MeOH in DCM. Fractions were collected and concentrated in vacuo to afford 12 as a 
purple solid (80 mg, 4%). 1H NMR (300 MHz, CDCl3): δ = 10.416 (s, 2H), 9.485 (d, J = 
4.65, 4H), 9.11 (m, 4H), 9.075 (d, J = 4.67, 4H), 8.260 (m, 4H). 
2.3.2.11 5, 10, 15-Tri-4-pyridylporphyrin 13 (26): 
5-(4-pyridyl)dipyrromethane 4 (500 mg, 2.3 mmol), trimethyl orthoformate 11 
(9 mL, 82.5 mmol), 4-pyridylcarboxaldehyde 3 (0.4 mL, 4.1 mmol) and anhydrous 
DCM (400 mL) were added to a flask and degassed by bubbling with argon for 30 min. 
In a separate flask, TCA (8.83 g, 54 mmol) was dissolved in anhydrous DCM (100 mL). 
The solution was added to the reaction mixture slowly over 15 min and stirred for 4 h. 
The reaction mixture was quenched with pyridine (15.6 mL) and stirred for 2 h. DDQ 
(0.3 g, 1.3 mmol) was added and stirred for 15 min. The aluminum foil was removed and 
the solvent was evaporated in vacuo to yield a black solid, which was left on high 
vacuum overnight. The black solid was preadsorbed onto silica and purified twice via 
automated flash chromatography using 5% MeOH in DCM. Preparative TLC, run in 8% 
MeOH in DCM gave 13 as a purple band, isolated as a purple solid (15 mg, 1.3%). 1H 
NMR (300 MHz, CDCl3) : δ = 10.355 (s, 1H), 9.436 (d, J = 4.7 Hz, 2H), 9.081 (m, 6H), 
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9.032 (d,  J = 4.7 Hz, 2H), 8.923 (m, 4H), 8.218 (m, 6H), -3.118 (s, 2H). Exact mass: 
calculated: 542.21; found: 542.2071 (M+H+) 
2.3.2.12 General procedure for the quaternization of porphyrin pyridyl groups 
with iodomethane (26): 
To an oven dried flask cooled under vacuum porphyrin (0.044 mmol) was added 
and purged with 3x with argon. 32 mL dry CHCl3 followed by 8 mL dry DMF was 
added via syringe. 3.5 mL (excess) CH3I was added and the solution was stirred for 12 
hours at RT. The solution was concentrated under vacuum to 1/4 the original volume. To 
the solution was then added 60 mL Et2O several times with subsequent decanting. The 
solid was then triturated with CH3CN, decanted and dried in vacuo to yield product. 
2.3.2.12.1 5-(N-methylpyridynium-4-yl) porphyrin P(5): 
Trituration yielded 0.002 g P(5).  Exact mass: calculated: 402.1713; found: 
402.1771. 
2.3.2.12.2 5,10-Di(N-methylpyridinium-4-yl) porphyrin P(5,10): 
Note that P(5,10) was soluble in CH3CN, so the last wash was filtered and 
evaporated to dryness to yield 0.001 g P(5,10). Exact mass: calculated: 494.2200; found: 
494.2140. 
2.3.2.12.3 5,15-Di(N-methylpyridinium-4-yl)porphyrin P(5,15): 
Trituration yielded 0.012 g P(5,15). 1H NMR (300 MHz, DMSO-d6): δ = 10.849 
(s, 2H), 9.859 (d, J = 4.7, 4H), 9.516 (d, J = 5.91, 4H), 9.245 (d, J = 4.7, 4H), 9.083 (d, J 




2.3.2.12.4 5,10,15-tri(N-methyl pyridinium-4-yl)porphyrin P(5,10,15): 
Trituration yielded 0.008 g P(5,10,15).  1H NMR (300 MHz, CDCl3): δ = 
10.866 (s, 1H), 9.860 (br s, 2H), 9.518 (m, 6H), 9.210 (m, 4H), 9.183 (m, 2H), 9.030 
(m, 4H), 8.970 (m, 2H), 4.981 (s, 9H), -3.660 (s, 2H). Exact mass: calculated: 
195.4200; found: 195.4242. 
2.4 Results 
The CD spectra shown in Figure 2.1 indicate that the WT Bcl-2 27-mer P1 
promoter sequence exists as a mixed parallel/anti-parallel G-quadruplex in the K+ BPES 
buffer in the absence of any added porphyrin ligand. The naked Bcl-2 27-mer CD 
spectrum shown in the Figure 2.1, (P/DNA = 0), exhibits typical G-quadruplex 
characteristic peaks and troughs at 245 nm, 265 nm and a shoulder at 290 nm (8).  The 
dashed line shown along the x-axis in Figure 2.1 is the measured ellipticity of the 
porphyrin in a DNA free solution. The CD spectra for the P(5,10,15)/Bcl-2 complexes 
having porphyrin to DNA ratios of 1, 2, 3, or 4 show that the CD signal for the G- 
quadruplex is largely the same for the complexes and the naked DNA although there is 
some attenuation of the characteristic peaks and troughs in the complex spectra. It is 
obvious that binding P(5,10,15) to the WT Bcl-2 27-mer P1 promoter sequence G- 
quadruplex does not perturb the folding of the DNA in the G-quadruplex. The CD 
spectra shown in Figure 2.2 are for the 2:1 complexes of the Bcl-2 G-quadruplex with 
P(5,15), P(5,10,15) and TMPyP4 (P(5,10,15,20)).  The CD spectra shown in Figure 2.2 
indicate that there is no change in the G-quadruplex structure upon complex formation 




Figure 2.1 CD spectra of WT 27-mer Bcl-2 G-quadruplex in the absence and presence 
of the P(5,10,15) ligand.   
The ellipticity at 265 nm is attenuated progressively as the porphyrin to DNA ration is 
increased from 0 to 4. The dashed line near y=0 is the ellipticity for the P(5,10,15) in a 




Figure 2.2 CD spectra are shown for the Bcl-2 G-quadruplex and its 2:1 complexes 
with P(5,15), P(5,10,15) and TMPyP4.  
The ellipticities at 265 nm and 295 nm are essentially the same for all three ligands and 




Figure 2.3 Electrospray ionization mass spectra for WT 27-mer Bcl-2 G-quadruplex 
and its complexes with P(5), P(5,10), P(5,15), and P(5,15,20).  
Panel A shows the mass spectrum obtained for a solution containing only the Bcl-2 
oligonucleotide at a concentration of 10 μM. Panels B–E show the mass spectra for the 
Bcl-2 oligonucleotide and its porphyrin complexes obtained in solutions containing 40 
μM P(5), 40 μM P(5,10), 40 μM P(5,15) and 40 μM P(5,15,20), respectively. 
The ESI mass spectrum for the WT Bcl-2 27-mer P1 promoter sequence G- 
quadruplex, and the spectra for the saturated complexes of the WT Bcl-2 27-mer P1 
promoter sequence G-quadruplex with P(5), P(5,10), P(5, 15) and P(5,10,15) are shown 
in Figure 2.3. The ESI mass spectra for the solutions containing P(5) or P(5,10) along 
with the Bcl-2 G-quadruplex, shown in Figure 2.3 B and C respectively, provide no 
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evidence for Bcl-2 complex formation with these ligands. The only peaks in the mass 
spectra shown in Panel B and Panel C of Figure 2.3 are for the parent DNA with a charge 
of -5 or -4, exactly the same as the spectrum shown in Panel A for the naked DNA.  The 
ESI mass spectrum for the solution containing P(5,15) along with the Bcl-2 G-quadruplex 
is shown in Panel D of Figure 2.3.   The spectrum for this solution which contains four 
moles of P(5,15) per mole of Bcl-2 G-quadruplex is consistent with significant complex 
formation. The new peaks with m/z values of 1908.3 and 2385.6 are attributed to a 
P(5,15)/Bcl-2 complex having a molar ratio of 2:1 and a charge of  -5 or -4 respectively. 
It should also be noted that no free or uncomplexed Bcl-2 is present in this solution. This 
result is consistent with a very large Ka for formation of the 2:1 P(5,15)/Bcl-2 complex.  
The ESI mass spectrum for the solution containing P(5,10,15) and the Bcl-2 G-
quadruplex is shown in Panel E of Figure 2.3.  The spectrum for this solution, which 
contains four moles of P(5,10,15) per mole of Bcl-2 G-quadruplex, is consistent with 
weaker complex formation. The new peaks with m/z values of 1947.4 and 2436.2 are 
attributed to a P(5,10,15)/Bcl-2 complex having a molar ratio of 2:1 and a charge of -5 or 
-4.  In this spectrum a peak with an m/z value of 1711.2 which corresponds to 
uncomplexed G-quadruplex with a charge of -5 is also seen.  The same peak (m/z = 
1711.2) is also seen as the predominant peak in the spectrum obtained for DNA in the 
ligand free solutions (Figure 2.3 Panel A). The ESI-MS spectra were obtained using 
ammonium acetate as the buffer and supporting electrolyte (in place of either Na+ or K+). 
The greater lability of the ammonium ion in comparison to either sodium or potassium 
ions reduces DNA counter ion adduction yields a cleaner mass spectrum.  Under these 
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conditions, the observation of the loss of the two NH4+ from between the stacked G-
tetrads in the quadruplex is problematic.  
Due to the limited solubility of the P(5), P(5,10), P(5,15) and P(5,10,15) 
porphyrin ligands, the ITC experiments were all done as reverse titrations in which a 
dilute solution of the DNA was added to a dilute solution of the porphyrin in the 
calorimeter cell (see Figure 2.4). Reverse titration is a common practice for systems with 
low solubility and yields thermograms that are easily fit to an independent site model with 
the CHASM© program (28) (see ITC data in Figure 2.4 panel C).  Typical ITC data for 
the titration of the P(5,15) porphyrin ligand with the Bcl-2 G-quadruplex are shown in 
Figure 2.4 panel A. The data shown in Figure 2.4 panel B are for the dilution of P(5,15), 
i.e. the curve shown is for the addition of buffer to the P(5,15) porphyrin titrate. The 
heats of dilution for these porphyrins were significant, a sign that the porphyrins in 
solution are undergoing some self-association. The data shown in Figure 2.4 panel C are 
the integrated heat data corrected for the heat of dilution. The best fit parameters and 
associated uncertainties for the non-linear regression fit of the ITC heat data are shown in 
the box in Figure 2.4 C. The expected value of n would be 0.5 for a complex having two 
ligands per mole of DNA since these data are for the reverse titration.  The ITC data for 
the P(5,15) and P(5,10,15) titrations were similar in that these two ligands bind with 
similar stoichiometry (2:1) and similar affinity (Ka ≈ 1×107).  The ITC data for the P(5) 
and P(5,10) titrations were similar in that these two ligands were not observed to bind and 
the titrations were almost identical to the blank titrations. The corrected data for the 
P(5,15) and P(5,10,15) titrations were fit with CHASM© to yield best fit values for K, 
ΔH, and n. Values of ΔG and -TΔS were calculated from the best fit parameters and are 
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reported in Table 2.1. The relative affinities for binding the four new porphyrin ligands 
and TMPyP4 to the WT Bcl-2 promoter sequence G-quadruplex are: KTMPyP4 ≈ KP(5,15) > 
KP(5,10,15) >>> KP(5,10), KP(5). The ITC and ESI-MS data are in agreement with respect to 
the relative affinities 
 
Figure 2.4 Panel A shows the thermogram for the addition of the 115 μM WT-27mer 
Bcl-2 titrant into 5 μM P(5,15), Panel B shows the thermogram for heat of 
dilution of the porphyrin solution, that is, the addition of buffer into 5 μM 
P(5,15), and Panel C shows the corrected enthalpogram for titration DNA 
into porphyrin ligand along with the model fit (▬) and best fit parameters 






Table 2.1 A Comparison of the thermodynamic parameters for binding the porphyrin 
ligands P(5), P(5,10), P(5,15), P(5,10,15) and TMPyP4 to G-quadruplex 
DNA. 
  
a The SPR data are for the interaction of the porphyrin ligands with a 26-mer human 
telomere G-quadruplex having the sequence: 5’-GGA TTG GGA TTG GGA TTG GGA 
TTG GG-3’ (26) 
 b The ITC data reported here are for the interaction of the porphyrin ligands with a 27- 
mer BCL-2 G-Quadruplex having the sequence: 5’-CGG GCG CGG GAG GAA GGG 
GGC GGG AGC-30. The data for the binding of TMPyP4 to the same G-quadruplex are 
from Nagesh et al. (9) 
2.5 Discussion 
The synthetic routes for all four model porphyrin ligands are shown in Scheme 
2.1 and all previous synthesis and synthetic methods are referenced. The synthesis of 
porphyrins P(5), P(5,15), and P(5,10,15) was accomplished utilizing the route reported 
by Goncalves et al. (26). This route provided these porphyrins in good yield. The 
synthesis of P(5,10) was accomplished by the modification of a synthetic route reported 
by Dogutan et al. (32). This new synthetic route provided for a more efficient means for 
the synthesis of the P(5,10) analogue as compared to the Goncalves et al. route. 
The binding of the new porphyrin ligands was compared to TMPyP4 for the 
purpose of determining the effects of the ligand’s solvent accessible surface area (SASA), 
charge, symmetry, and geometry on the thermodynamics of their interactions with G-
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quadruplex DNA.  The thermodynamic data given in Table 2.1 yield a couple of 
surprises.  The binding of the P(5,15) and to a lesser degree the P(5,10,15) compounds 
seems to be tighter than expected, while the binding of the P(5,10) compound appears to 
be weaker than expected. The Lewis group and others have previously suggested that the 
two binding modes observed for the interaction of TMPyP4 with G-quadruplexes in 
general, and more specifically with c- MYC, Bcl-2, and K-ras promoter sequence G-
quadruplexes, are 1) an “end binding” mode, and 2) an “intercalation mode” (7, 8, 10).  
The end-binding mode is generally accepted in the literature and is not controversial in 
that stacking of the planar porphyrin ligand, TMPyP4, on a terminal G-tetrad is 
consistent with simple π-π stacking and similar to guanine self-association. On the other 
hand, the proposed intercalation mode is neither proven nor does it resemble simple self-
association or the π-π stacking of the end binding interaction. However, the Lewis group 
as well as others have published numerous studies that suggest that intercalation is 
plausible, not only from the saturation stoichiometry which varies as the number of 
stacked tetrads plus one (12), but also from the reduction in bound ligands from 4 to 2 as 
the ligand becomes non-planar (15).  Modeling studies show that TMPyP4 can intercalate 
between the G-tetrads and that the structure of the G- quadruplex is not affected (33).  All 
of these results are also supported by CD data that indicate no change in the G-
quadruplex CD spectrum on formation of the 4:1 TMPyP4/DNA complex. There is also 
no induced CD signal for bound TMPyP4 until excess ligand is present, with excess 
ligand more weakly bound to the exterior of the G- quadruplex, possibly in the grooves 
(15). The thermodynamic signatures for these two modes are characteristic in that the 
“end binding” mode is accompanied by a small favorable ΔH and a large favorable -TΔS 
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term which drives the complex formation, while the “intercalation” mode is driven by a 
large favorable ΔH and a negligible change in entropy (7).  Using these same arguments, 
the binding of the P(5,15) ligand is described as “intercalation” and the binding of the 
P(5,10,15) ligand as “end binding”. In comparison to TMPyP4 which forms G-
quadruplex complexes having a saturation stoichiometry of 4:1, the P(5,15) and 
P(5,10,15) only form 2:1 complexes with the BCL-2 promoter sequence G-quadruplex. 
The affinities reported in Table 3.1 for binding P(5,15) and P(5,10,15) to the 
BCL-2 G-quadruplex are in general agreement with the affinities reported by Goncalves et 
al. (26) for binding these same ligands to a human telomere G-quadruplex.  In 
comparison to this study’s ITC results for G-quadruplex complex formation with these 
ligands, the SPR experiments of Goncalves et al. (26) yield a smaller ΔG° value for the 
interaction of P(5,15) (-8.3 kcal/mol vs. -9.4 kcal/mol by ITC), a similar ΔG value for the 
interaction of P(5,10,15) (-7.1 kcal/mol vs. -6.7 kcal/mol by ITC), and a smaller ΔG° 
value for the interaction of TMPyP4 (-8.4 kcal/mol vs. -9.0 kcal/mol, the average ΔG° for 
the mode 1 and mode 2 reactions as determined by ITC). All of these values are in good 
agreement particularly since the Goncalves results are for binding to a human telomere G-
quadruplex instead of the Bcl-2 G-quadruplex used in this study which exists as an 
ensemble of at least three folded isomers. The biggest differences are that Goncalves et 
al. (26) reports a significant affinity for binding the P(5,10) ligand to a human telomere 
G-quadruplex, while complex formation between the P(5,10) ligand and the Bcl-2 
promoter sequence G-quadruplex in either ITC or ESI-MS experiments was not observed 
in this work. Additionally Goncalves et al. (26) failed to find the expected 4:1 
stoichiometry for the TMPyP4 complex with the human telomere (34).  The SPR study of 
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Federici et al. reports two binding modes and a saturation stoichiometry of 4:1 for the 
binding of TMPyP4 to the c-MYC promoter sequence G-quadruplex (35). Their two 
reported affinities are: K1 ≈ 1.3×108 (ΔG = -11.0 kcal/mol) and K2 ≈ 7.7×105 (ΔG° = -8.0 
kcal/mol). These are in excellent agreement with the previously reported values for the 
interaction of TMPyP4 with the c-MYC, Bcl-2, and K-ras promoter sequence G- 
quadruplexes (7, 8, 10). 
Whether the binding of P(5,15) is through end-binding, intercalation, or binding in 
a G-quadruplex groove, its apparent high affinity points us in a new direction with respect 
to designing G-quadruplex interactive ligands. In comparison to TMPyP4, the P(5,15) 
ligand has a smaller SASA, and has a charge of only +2. However, P(5,15) binds to the 
Bcl-2 G-quadruplex with almost the same affinity as TMPyP4, ΔG° = -9.4 kcal/mol vs. -
10.4 kcal/mol for TMPyP4 (for binding the first two moles of TMPyP4).  It also appears 
to bind by the “intercalation mode” vs. the mode 1 interaction for TMPyP4 which has 
been assigned to “end binding”. Perhaps even better G-quadruplex ligands could be 
synthesized to take advantage of the trans (5,15) substitution pattern on the core 
porphyrin, but with changes in the substituent charge or shape to produce stronger 
interactions with either the G-tetrad(s), loops, or grooves of the G-quadruplex (36-38).  
The weaker affinity of the P(5,10,15) ligand in comparison to TMPyP4 and its apparent 
end binding are more difficult to explain. For example, why does the removal of a single 
pyridinium substituent from TMPyP4 result in the loss of almost 3.5 kcal in the binding 
energy? Perhaps the explanation is that the substituent pyridinium groups in TMPyP4 are 
interacting with the loops, grooves and/or tail residues in the G-quadruplex and the loss of 
one interaction is destabilizing. The Arya group has begun to exploit dual recognition 
 
57 
with conjugated ligands incorporating both a planar moiety to base stack with an 
aminoglycoside to bind in the quadruplex groove (36, 37).  A better understanding of the 
G-quadruplex interactions with model porphyrin ligands used in this study as well as 
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CALORIMETRIC AND SPECTROSCOPIC INVESTIGATIONS OF THE BINDING 
OF METALLATED PORPHYRINS TO G-QUADRUPLEX DNA 
Previously published in Biochimica et Biophysica Acta - General Subjects 2015, 
1860, 902-909 and reproduced with permission 
3.1 Abstract 
The human telomere contains tandem repeat of (TTAGGG) capable of forming a 
higher order DNA structure known as G-quadruplex. Porphyrin molecules such as 
TMPyP4 bind and stabilize G-quadruplex structure. Isothermal titration calorimetry 
(ITC), circular dichroism (CD), and mass spectrometry (ESI-MS) were used to 
investigate the interactions between TMPyP4 and the cobalt(III), nickel(II), copper(II), 
and zinc(II) complexes of TMPyP4 (e.g. Co-TMPyP4) and a model human telomere G-
quadruplex (hTel22) at or near physiologic ionic strength ([Na+] or [K+] ≈ 0.15 M). The 
apo-TMPyP4, Ni-TMPyP4, and Cu-TMPyP4 all formed complexes having a saturation 
stoichiometry of 4:1, moles of ligand per mole of DNA. Binding of apo-TMPyP4, Ni-
TMPyP4, and Cu-TMPyP4 is described by a “four-independent-sites model”. The two 
highest-affinity sites exhibit a Ka in the range of 108 to 1010 M−1 with the two lower-
affinity sites exhibiting a Ka in the range of 104 to 105 M−1. Binding of Co-TMPyP4, and 
Zn-TMPyP4, is best described by a “two-independent-sites model” in which only the 
end-stacking binding mode is observed with a Ka in the range of 104 to 105 M−1. In the 
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case of apo-TMPyP4, Ni-TMPyP4, and Cu-TMPyP4, the thermodynamic signatures for 
the two binding modes are consistent with an “end stacking” mechanism for the higher 
affinity binding mode and an “intercalation” mechanism for the lower affinity binding 
mode. In the case of Co-TMPyP4 and Zn-TMPyP4, both the lower affinity for the “end-
stacking” mode and the loss of the intercalative mode for forming the 2:1 complexes with 
hTel22 are attributed to the preferred metal coordination geometry and the presence of 
axial ligands.  The preferred coordination geometry around the metal center strongly 
influences the energetics of the interactions between the metallated-TMPyP4 and the 
model human telomeric G-quadruplex. 
3.2 Introduction 
Human telomeric DNA offers an attractive therapeutic target in cancer research 
(1). Telomerase, an enzyme that catalyzes telomeric extension in the 3′ overhang of 
eukaryotic DNA, is expressed in a majority of cancer cells (2). Telomeric extension 
inhibits the degradation of chromosomal DNA and thereby allows for replicative 
immortality, whereas normal cells incur telomeric truncation of 50–200 bp with each 
replicative cycle (3). Allosteric inhibition of telomerase activity would allow for 
truncation without extension and therefore allow induction of senescence in malignant 
cells (4). 
The human telomere contains 5–15 kb pairs consisting of the repeat unit 
(TTAGGG)n (3). These guanine-rich sequences are able to undergo conformational 
changes to form a higher order DNA structure, consisting of a series of planar G-tetrads, 
which are then stacked through π–π interactions to form a G-quadruplex (5). G-
quadruplexes formed in the 3′-single strand overhang of the human telomere have been 
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studied in cells (6, 7). Stabilization of this structure allows for the inhibition of 
telomerase (4). Small molecules with selectivity and high affinity for G-quadruplex DNA 
have been studied as potential therapeutic agents (8–13). Porphyrins are known to inhibit 
telomerase with low cytotoxicity (8, 9). The interactions of the planar cationic porphyrin 
TMPyP4 (meso-tetra (N-methyl-4-pyridyl)porphyrin tetrachloride, which exhibits 
selectivity and high affinity for G-quadruplex DNA, have been studied extensively as a 
model for drug stabilization of quadruplex DNA (8, 9, 14, 15). 
The Lewis group has previously published several studies of TMPyP4 interactions 
with G-quadruplex DNAs (13–17). It has been demonstrated that TMPyP4 binds in an n 
+ 1 fashion, where n is the number of stacked tetrads in the quadruplex core. For 
example, a G-quadruplex having three stacked G-tetrads, typically binds four moles of 
TMPyP4 per mole of quadruplex DNA, with two moles of the TMPyP4 ligand binding 
by a higher affinity mode, attributed to an end binding mechanism driven largely by a 
favorable entropy contribution, and two moles binding by a lower affinity, intercalative 
mode driven by favorable changes in enthalpy.  Le et al. has also shown that planarity of 
the ligand is needed for a complete saturation of the G-quadruplex, as TMPyP4 binds 
with a 4:1 ratio while TMPyP3 and TMPyP2 only bind with 2:1 ratio (14). By 
modulating the number of pyridyl substituents on the porphyrin, it was demonstrated that 
charge, geometry, and symmetry also play important roles in the thermodynamics and 
selectivity of binding porphyrins to G-quadruplex DNA (13). In this study, the 
incorporation of four third row transition metals into the center of the porphyrin ring to 
form metallated cationic porphyrins and its effects on binding were examined: Co-
TMPyP4, Ni-TMPyP4, Cu-TMPyP4, and Zn-TMPyP4. The goal was to understand how 
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the presence of the metal, the additional positive charge, and the geometry of the metal 
ion environment would affect the interactions of these metallated porphyrins with G-
quadruplex DNA. Obviously the metallated porphyrins are not being developed as 
potential drug compounds since the presence of the transition metals would be expected 
to render these compounds to be either toxic or even carcinogenic. In effect, this study 
was performed in an attempt to probe the effects of the metal ions on the binding 
thermodynamics for the metallated porphyrin compounds in comparison to the parent 
porphyrin, TMPyP4, and on the possible structures for their complexes with G-
quadruplex DNA, again in comparison to the parent porphyrin, TMPyP4. 
Isothermal titration calorimetry, in combination with ESI-MS and CD 
spectroscopy, was used to characterize the interactions of the metal containing porphyrins 
with a model human telomeric DNA sequence, hTel22. Although previous reports have 
studied some aspects of these interactions, no one has examined these specific metallated 
porphyrins using G-quadruplex DNA and isothermal titration calorimetry (18–20). 
3.3 Materials and methods 
The 22-mer oligonucleotide, hTel22, having the sequence 5′-A GGG TTA GGG 
TTA GGG TTA GGG-3′, was obtained from Midland Oligos (Midland, TX). DNA stock 
solutions were prepared by reconstituting the lyophilized oligonucleotide into its 
respective phosphate buffer. The buffer concentrations consisted of 20 mM phosphate 
and 150 mM total Na+ or K+ as the supporting electrolyte (the chloride form of the salt 
was used), as well as 1 mM EDTA, at a pH of 7.0. Oligonucleotide was exhaustively 
dialyzed (1000 MW cutoff membrane) against two changes of buffer solution (1 L, 24 h 
each) at 4 °C. The DNA stock concentrations were verified using UV–Vis spectroscopy. 
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DNA was annealed by quickly heating to 98 °C, holding for 10 min and then cooling to 5 
°C over a 3 h period. The molar absorption coefficient was determined using a nearest-
neighbor method for single-stranded DNA (21). 
Co-TMPyP4 (Co3+), Ni-TMPyP4, Cu-TMPyP4, Zn-TMPyP4, and apo-TMPyP4 
were purchased as the chloride salts from Frontier Scientific (Logan, UT). The purity of 
the commercial porphyrins was confirmed by thin layer chromatography (TLC), UV–Vis 
and NMR spectroscopy as provided by the company. Porphyrin samples were prepared 
by careful weighing and dissolving in the final dialysate buffer for respective 
experiments. Concentrations of the metallated porphyrin ligand solutions were 
determined by weight as the published extinctions coefficients were unreliable for the 
metallated porphyrins in the phosphate buffers used in this study. 
ESI-MS experiments of hTel22 porphyrin complexes were carried out on a 
Bruker MicrOTOFQ mass spectrometer. Data acquisition was set to operate in negative 
ion mode. All experiments were performed in 50 mM ammonium acetate buffer (pH 7.0) 
containing 20% HPLC grade methanol. The hTel 22-mer G-quadruplex sample was 
dialyzed against three changes of buffer, 24 h each, at 4 °C. Stock solutions of the 
porphyrin were prepared in the final dialysate buffer. The ESI-MS samples were prepared 
by stepwise, slow addition of porphyrin into hTel22 solution. The MS capillary voltage 
was set to +3500 V, dry N2 gas flow was adjusted to 0.5 L/min at 110 °C, and the G-
quadruplex/porphyrin samples were directly infused into the MS by using a kD Scientific 
syringe pump set to a flow rate of 200 μL/h. Data processing was performed using Bruker 
Daltonics Data Analysis program. 
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CD experiments were performed with an Olis DSM-20 spectropolarimeter 
(Bogart, GA). All measurements were performed at 25 °C using a 1 cm quartz cuvette 
and covering a spectral range of 220–320 nm. 
ITC experiments were performed using a VP-ITC calorimeter (GE Healthcare). A 
typical ITC experiment consisted of either 28 (10 μL) or 56 (5 μL) injections of a dilute 
porphyrin solution into a dilute hTel22 DNA solution. Blank titrations were determined 
by injecting porphyrin into buffer solution. These dilution heats were subtracted from the 
ITC data for the DNA-porphyrin titrations, yielding dilution corrected heats. Corrected 
ITC titrations were then fit with a nonlinear regression algorithm using CHASM, a data 
analysis program developed in the Lewis laboratory (22). 
3.4 Results 
The ESI mass spectra for solutions containing mixtures of metallated-TMPyP4 
complexed to hTel22 are shown in Figure 3.1. In comparison to the ESI mass spectra for 
the solution containing only hTel22 (11), ESI mass spectra for mixture solutions of 
metallated-TMPyP4/hTel22 did not contain any m/z peaks of 1740.5 or 2321.0, which 
correspond to the −4 and −3 unbound hTel22 species. In all four cases, the ESI mass 
spectra shown in Figure 3.1 provide evidence of complex formation between hTel22 and 
metallated-TMPyP4. In contrast to the ESI mass spectrum for a solution containing apo-
TMPyP4/hTel22 in which several m/z peaks corresponding to the highest 4:1 saturation 
stoichiometry could be observed, the ESI mass spectra for solutions containing 
metallated-TMPyP4/hTel22 only provide evidence for the formation of 2:1 complexes for 
the Co- and Zn-TMPyP4 ligands and only provide evidence for the formation of the 3:1 
complexes of the Ni- and Cu-TMPyP4 ligands. Furthermore, the natural isotopes of the 
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metal (Co, Ni, Cu, and Zn) result in the ESI mass spectra being more complex than 
observed for apo-TMPyP4. However, the isotopic distribution patterns observed in the 
ESI mass spectra matched with those simulated by using the Bruker Daltonics Data 
Analysis program. 
Circular dichroism spectropolarimetry was used to investigate the effect of 
titrating apo-TMPyP4 and metallated-TMPyP4 into hTel22 G-quadruplex DNA. The CD 
spectra for the titrations of the apo-TMPyP4 and metallated-TMPyP4 into hTel22 G-
quadruplex in 150 mM Na+ are illustrated in Figure 3.2. The CD spectra of the hTel22 G-
quadruplex, in the absence of any ligand, exhibited characteristic peaks at 245 nm and 
295 nm as well as a trough at 265 nm (23). Additions of apo-TMPyP4 into hTel22 
resulted in significant attenuation in the CD signal at 265 nm and to a lesser extent in the 
CD signal at 295 nm. The titrations of metallated-TMPyP4 exhibited differential effects 
on the CD signals of the hTel22 G-quadruplex depending on the metal center in the 
metallated-TMPyP4. Titrations of Co- and Zn-TMPyP4 exhibited negligible effects on 
the CD signal of hTel22 up to 6 equivalence of the ligands. Addition of Ni- and Cu-
TMPyP4, however, resulted in significant attenuation in the CD signals at both 265 nm 
and 295 nm. These signal attenuations, caused by addition of Ni- and Cu-TMPyP4, are 
even more pronounced than the signal attenuations observed for the additions of the apo-
TMPyP4 into hTel22 at the same molar ratio of ligand/DNA. Notably, the signal 







Figure 3.1 Electrospray ionization mass spectra for solutions containing hTel22 G-quadruplex DNA and excess amounts Co-
TMPyP4 (panel A), Ni-TMPyP4 (panel B), Cu-TMPyP4 (panel C), and Zn-TMPyP4 (panel D).
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Similar titration experiments were conducted for additions of apo- and metallated-
TMPyP4 into hTel22 in potassium buffer. The CD titrations performed in 150 mM K+ 
phosphate buffer are shown in Figure 3.3. In contrast to CD signals for the hTel22 
observed under Na+ conditions, the CD signals for the hTel22 observed under K+ 
conditions are clearly distinctive with a characteristic shoulder at 265 nm and a peak at 
295 nm (23). Additions of apo-TMPyP4, Ni-TMPyP4, and Cu-TMPyP4 into K+ form 
hTel22 all resulted in significant attenuation in the CD signal at 295 nm. Similar to CD 
titrations performed under Na+ conditions, the addition of Co- and Zn-TMPyP4 had 
minimal effect on the CD signals of K+ form hTel22 up to 6 equivalence of the ligands. 
The signal attenuations near 295 nm were also accompanied by red shifts.  
 
Figure 3.2 CD titration data for complexation of the hTel22 G-quadruplex with apo- 
and metallated-TMPyP4 in 150 mM Na+ BPES buffer.  
CD spectra of the Na+ salt hTel22 G-quadruplex are represented as (▬) while the spectra for the 
titrations of apo- and metallated-TMPyP4 into hTel22 are shown in colors. The CD titration data 
were collected at 1:1, 2:1, 3:1, 4:1, and 6:1 ratios of ligand per DNA and were corrected for the 
signal of ligands at the corresponding ratios. Arrows indicate the shifts at the characteristic 
wavelengths for Na+ hTel22. 
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CD spectra are difficult to interpret and the subtle changes in the 295 region are 
only noted here to indicate that the strongly binding compounds, TMPyP4, Ni-TMPyP4, 
and Cu-TMPyP4 are influencing the structure of the hTel22 G-quadruplex. The important 
point is that there are no significant changes in the G-quadruplex signature peaks in the 
CD titrations employing the more weakly interacting Co and Zn porphyrins. Explaining 
the small blue and red shifts observed in the 295 nm region for both the Na+ and K+ 
hTel22 G-quadruplexes when titrated with TMPyP4, Ni-TMPyP4, or Cu-TMPyP4 is 
beyond the scope of this manuscript.  
 
Figure 3.3 CD titration data for complexation of the hTel22 G-quadruplex with apo 
and metallated-TMPyP4 in 150 mM K+ BPES buffer.  
CD spectra of the Na+ salt hTel22 G-quadruplex are represented as (▬) while the spectra for the 
titrations of apo and metallated-TMPyP4 into hTel22 are shown in colors. The CD titration data 
were collected at 1:1, 2:1, 3:1, 4:1, and 6:1 ratios of ligand per DNA and were corrected for the 
signal of ligands at the corresponding ratios. Arrows indicate the shifts at the characteristic 
wavelength for K+ hTel22 
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To further investigate the interactions between hTel22 G-quadruplex with both 
the apo-TMPyP4 and metallated-TMPyP4, a series of ITC experiments in two different 
buffer conditions was performed: 150 mM Na+ and 150 mM K+. As shown in Figures 4.4 
and 4.5, the titration experiments of TMPyP4 (both apo- and metallated-) into hTel22 G-
quadruplex are more complex than the TMPyP4 titrations previously reported for the 
addition of TMPyP4 to oncogene promoter sequence G-quadruplexes for c-MYC, BCl-2 
and K-ras (14–17). Figure 3.4 shows the titration data of the apo- and metallated-
TMPyP4 into hTel22 G-quadruplex in 150 mM Na+ BPES buffer. The titrations shown in 
Figure 3.4 have been corrected for the heats of dilution of the ligand (apo- and 
metallated-TMPyP4) into buffer. The titration data for apo-TMPyP4, Ni-TMPyP4, and 
Cu-TMPyP4, shown in the left panel of Figure 3.4, could not be adequately analyzed 
using the two-binding site model provided by the ITC manufacturer; instead they were fit 
to a three-event model using CHASM ITC data analysis software (22). However, the 
titration data for Co-TMPyP4 and Zn-TMPyP4, shown on the right panel of Figure 3.4, 
were adequately fit to a simple single binding event either by using the commercial 
software (Origin) or software developed in the Lewis laboratory (CHASM).  
The titration data of the apo- and metallated-TMPyP4 into hTel22 G-quadruplex 
in 150 mM K+ BPES buffer are shown in Figure 3.5. The titrations shown in Figure 3.5 
have been corrected for the heats of dilution of the ligand (apo- or metallated-TMPyP4) 
into buffer. Similar to the titration experiments performed in Na+ buffer, titration data of 
the apo-TMPyP4, Ni-TMPyP4, and Cu-TMPyP4, shown in the left panel of Figure 3.5, 
were fit to a three-event model using CHASM while the titration data for Co-TMPyP4 
and Zn-TMPyP4, shown on the right panel of Figure 3.5, were fit to a single binding 
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event, Co, or to a two binding event model, Zn. Notably, for ITC experiments performed 
in both potassium and sodium conditions, the titrations of apo- TMPyP4, Cu-TMPyP4, 
and Ni-TMPyP4 into hTel22 exhibit saturation stoichiometries occurring near a molar 
ratio of 4:1. On the other hand, titrations of Co-TMPyP4 and Zn-TMPyP4 into hTel 22-
mer exhibit a 2:1 saturation stoichiometry. 
 
Figure 3.4 Typical nonlinear regression fits for the titration of apo (○) andmetallated-
TMPyP4 into hTel22 G-quadruplex in 150 mM K+ BPES buffer.  
Titration data ofmetallated-TMPyP4 are represented as following: Co-TMPyP4(■), Ni-
TMPyP4 (▲), Cu-TMPyP4 (▼), and Zn-TMPyP4 (●). The titration data shown on the 
left panel were fit to a three-event model and the titration data shown on the right panel 
were fit to a single-event model. The non-linear best fits are shown in red. 
 
Table 3.1 Thermodynamic parameters obtained from ITC experiments for the 





Table 3.2 Thermodynamic parameters obtained from ITC experiments for the 
formation of metallated-TMPyP4 complexes with hTel22 G-quadruplex in 
150 mM Na+ buffer conditions. 
 
3.5 Discussion 
The Lewis group has recently reported on the use of ESI-MS to reveal the 
complex species formed and the saturation stoichiometry for ligand/DNA complexes (11, 
13, 14, 24, 25). Similar to the mass spectrometry data obtained for TMPyP4 complexed 
with a 27-mer Bcl-2 promoter sequence G-quadruplex, ESI mass spectra indicated that 
the planar cationic porphyrin TMPyP4 exhibited a 4:1 saturation stoichiometry with 
human telomeric G-quadruplex hTel22. The absence of any m/z peaks corresponding to 
free DNA in the ESI mass spectrum for a solution containing apo-TMPyP4 and hTel22, 
is indicative of the high affinity exhibited by the TMPyP4 toward the hTel22 G-
quadruplex. Similarly, there were no m/z peaks corresponding to the free DNA in the ESI 
mass spectra for solutions containing any of the four different metallated-TMPyP4 
ligands and hTel22 G-quadruplex DNA. This suggests that all four metallated-TMPyP4 
ligands bind to hTel22 with moderate to high affinity under the conditions of these 
experiments. However, in contrast to the ESI-MS experiments performed with the apo-
TMPyP4, m/z peaks corresponding to ligand/DNA ratios greater than 3:1 for the Ni, Cu, 
and Zn compounds or greater than 2:1 for the Co-TMPyP4 compound, were not 
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observed. Furthermore, the m/z peaks observed in the mass spectrum for the apo-
TMPyP4/hTel22 complex are much sharper than those observed for the metallated-
TMPyP4/hTel22 complexes. 
Even though Co-TMPyP4 only exhibits a maximum 2:1 stoichiometry with 
hTel22, while the remaining Cu-TMPyP4, Ni-TMPyP4, and Zn-TMPyP4 exhibited a 
maximum of 3:1 stoichiometry, these ratios are in poor agreement with the ITC endpoints 
that indicate saturation stoichiometries of 4:1 for the apo-TMPyP4 (confirmed by ESI-
MS), and 4:1 for the Ni and Cu TMPyP4 compounds (where the ESI-MS data show 
maximum mole ratios of 3:1). An explanation for these differences is that the 4:1 
metallated porphyrin complexes have lower solubility and precipitate in the solutions 
prepared for the ESI-MS experiments. The very small amounts of the 3:1 Zn-
TMPyP4/hTel22 complex observed in the ESI-MS spectrum may be the result of some 
nonspecific ligand binding whereas the 2:1 mol ratio species observed in both the Co-
TMPyP4/hTel22 and Zn-TMPyP4/hTel22 solutions are in agreement with the ITC 
endpoints. We have elected to use the ITC stoichiometries with some caution since they 
are not universally confirmed by the ESI-MS experiments. 
The CD titration experiments revealed useful insights into the type of interactions 
that a particular ligand may impose on the structure of the DNA.  The change in signal of 
the G-quadruplex was observed to determine how binding of a given metallated-TMPyP4 
may alter the structure of the hTel22 G-quadruplex.  Several conclusions can be drawn 
from the CD titration experiments performed under both Na+ and K+ conditions. First, the 
interactions of the apo-TMPyP4 with the hTel22 G-quadruplex proceed with only slight 
modification of the telomeric G-quadruplex solution structure. Secondly, the interactions 
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of both Co-TMPyP4 and Zn-TMPyP4 with the hTel22 G-quadruplex proceed through a 
mechanism that results in essentially no change in the structure of the hTel22 G-
quadruplex. Thirdly, the CD titration experiments suggest that the interactions of both Ni-
TMPyP4 and Cu-TMPyP4 with the hTel22 G-quadruplex are most similar to the 
interactions of apo-TMPyP4 with the hTel22 G-quadruplex, albeit exhibiting a greater 
change in the hTel22 G-quadruplex solution structure. 
The Lewis laboratory’s previous work has documented that the interactions 
between the planar cationic porphyrin, TMPyP4, and any G-quadruplex DNA, having 
three stacks of G-tetrads (e.g. 27-mer Bcl-2, 27-mer c-myc, and 30-mer K-ras), can 
typically be described by a model which includes two different binding modes, with each 
binding mode having two identical binding sites. The higher affinity binding mode is 
predominantly driven by the change in entropy while the lower affinity binding mode is 
driven by the change in enthalpy (14–17). The high affinity binding site has been 
attributed to “end-stacking” of the planar porphyrin to the top or bottom of the G-
quadruplex core while the lower affinity site has been attributed to intercalation of the 
porphyrin between adjacent G-tetrads in the G-quadruplex core (14). 
This study was initially designed to determine/understand how the preferred 
coordination geometry around the metal center, in a series of metallated-TMPyP4 
ligands, might influence the energetics of the interactions between the metallated-
TMPyP4 ligands and model 22-mer human telomeric G-quadruplex constructs. 
Specifically, the interactions between the metallated-TMPyP4 and hTel22 would be 
compared to the interactions between apo-TMPyP4 and hTel22. However, the 
thermograms for the titration of apo-TMPyP4 into hTel22, in either Na+ or K+ solutions, 
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are more complicated than expected. The presence of an additional event in the early part 
of the titrations, specifically between 0 and 1 mol ratio of TMPyP4 to DNA, indicates 
that the previously proposed model (4 sites and two modes) for the interactions of 
TMPyP4 with for example the c-MYC promoter sequence G-quadruplex is not adequate 
to describe the interactions between apo-TMPyP4 and hTel22. The additional reaction in 
the early part of the hTel22 titrations required us to use ITC analysis software developed 
in the Lewis laboratory to fit these titration data to a three-event model. The 
thermodynamic parameters for the interactions between apo-TMPyP4 and hTel22 in 
either Na+ or K+ solutions are given in Table 3.1. 
Given the drastic difference in structural complexity between the K+ form and the 
Na+ form of telomeric G-quadruplex, as indicated by the CD experiments, the 
interactions between apo- TMPyP4 and hTel22 would be expected to be accordingly 
different. These differences are most apparent in the first reaction occurring in the early 
part of the titrations, i.e. the binding affinity exhibited by apo-TMPyP4 toward hTel22 in 
K+ form is almost an order of magnitude higher than for the Na+ form. This difference in 
binding affinity and the corresponding binding free energy (ΔΔG1 = −1.3 kcal/mol) of the 
first reaction is the result of the compensating effect between the enthalpy and entropy 
change terms. For the Na+ hTel22 G-quadruplex, the first reaction is predominantly 
driven by the enthalpy change, while the first reaction for the K+ hTel22 G-quadruplex is 
mainly driven by a change in entropy. Beyond the differences in the energetic profiles for 
the first reaction, the second and third reactions exhibit some similarities in their binding 
energetics: e.g. the second reaction is approximately two to three orders of magnitude 
greater in terms of binding affinity in comparison to the third reaction (or ΔΔG2–3 = ΔG2 − 
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ΔG3 of approximately −3 to −4 kcal/mol). Entropy changes provide the driving force for 
the second reaction while enthalpy changes drive the third reaction. 
Even though we can only speculate what the first reaction may be in these hTel22 
titrations, the second and third reactions are consistent (at least in terms of their 
thermodynamic profiles) with the previous model for binding TMPyP4 to G-quadruplex 
DNA. In other words, the second reaction is likely an “end-stacking” interaction to bind 
the second mole of TMPyP4 to form the (TMPyP4)2(hTel22) complex species and the 
third reaction is attributed to the “intercalation” of two additional moles of TMPyP4 to 
form the (TMPyP4)4(hTel22) complex species. The additional heat in the early part of the 
apo-TMPyP4 (or the metallated-TMPyP4) titration of hTel22 is unique to titrations of the 
human telomeric G-quadruplex. 
There are two plausible explanations for the extra heat and apparent increased 
affinity for binding the first mole of TMPyP4 to hTel22. One explanation would be that 
the hTel22 G-quadruplex has a solution structure wherein one end of the G-quadruplex 
core binds TMPyP4 much more tightly than the other end of the G-quadruplex core. A 
second and more likely explanation is that there is a ligand induced structural 
reorganization of the hTel22 G-quadruplex that accompanies binding of the first mole of 
TMPyP4. The second explanation finds support in the fact that hTel22 G-quadruplex is 
known to exhibit structural complexity in the form of multiple foldamers in dynamic 
equilibrium. For example, Phan and Patel have published NMR studies which suggested 
that the two-repeat human telomeric sequence d(TAGGGTTAGGGT) can form both 
parallel form and anti-parallel folded structures in 100 mM K+ and the two foldamers are 
in dynamic equilibrium at room temperature (26).  The first reaction in the titration of 
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apo-TMPyP4 to hTel22 G-quadruplex can be described as the apo-TMPyP4 binding 
simultaneously to multiple hTel22 foldamers; this binding is coupled with some ligand-
induced refolding of hTel22. It is conceivable that apo-TMPyP4 exhibits a higher affinity 
toward a specific hTel22 G-quadruplex topology and that this conformational selection 
shifts the dynamic equilibrium between the foldamers to a new equilibrium populated by 
the most thermodynamically favored apo-TMPyP4/hTel22 complex. 
The titration data for the interactions between hTel22 and metallated-TMPyP4 
have also been analyzed using the appropriate models. The thermodynamic parameters 
for the interactions between the metallated-TMPyP4 and hTel22, in solutions containing 
either Na+ or K+, are shown in Tables 3.2 and 3.3. 
As previously noted in the Results section, the thermograms for titration of either 
Co-TMPyP4 or Zn-TMPyP4 to hTel22 are very different from the titration experiments 
of apo-TMPyP4 to hTel22. Not only do these thermograms mostly lack the initial early 
reaction between 0 and 1 M ratio, but these thermograms also do not exhibit the classical 
“check mark” pattern as previously observed for c-MYC, Bcl-2 or K-ras G-quadruplex. 
Instead, the titrations of either Co-TMPyP4 or Zn-TMPyP4 to hTel22 exhibit a simple 
sigmoidal curve. The ITC experiments provide strong evidence that the presence of a 
metal in the center of the metallated-TMPyP4 plays a significant role in the interactions 
between these porphyrins and hTel22 G-quadruplex.  
Interactions between Co-TMPyP4 and hTel22 exhibit the lowest binding affinity 
among the series of metallated-TMPyP4 under both Na+ and K+ conditions. These 
binding affinities of Co-TMPyP4 to hTel22 are most comparable to the binding affinities 
determined for the third reaction in the titration of apo-TMPyP4 to hTel22. The enthalpic 
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and entropic contributions for binding of Co-TMPyP4 to hTel22, however, are more 
consistent with the second reaction in the titration of apo-TMPyP4 to hTel22. Based on 
the observation from the CD titration experiments in which subsequent addition of the 
Co-TMPyP4 resulted in almost no change in the CD signal of the hTel22 and the binding 
energetics obtained from ITC experiments, the binding of Co-TMPyP4 to hTel22 likely 
occurs via an exterior or “end-stacking” like mechanism. Except for a coordinating cobalt 
at the center of the porphyrin ring, Co-TMPyP4 is structurally similar to the apo-
TMPyP4. The geometry and ligand environment around the cobalt center in Co-TMPyP4 
must therefore account for the significant reduction in binding affinity and a complete 
loss of the “intercalative” mode as observed for binding of apo-TMPyP4 to hTel22.  
Zn-TMPyP4 exhibits some similarity to Co-TMPyP4 in terms of its binding to 
hTel22, although its binding affinities toward hTel22 are slightly higher than Co-
TMPyP4 under both Na+ and K+ conditions. The interactions of Zn-TMPyP4 to hTel22 in 
Na+ conditions can be modeled via a single binding event which is predominantly driven 
by enthalpy change. The interactions of Zn-TMPyP4 to hTel22 in K+ conditions, 
however, had to be modeled by two overlapping binding processes with the higher 
affinity binding driven by enthalpy change while the lower affinity binding is driven by 
entropy change. Although the interaction between Zn-TMPyP4 and hTel22 in K+ 
conditions can be described via a two binding-process, the enthalpic and entropic 
contributions are not consistent with a ligand binding proceeding through “end-stacking” 
followed by “intercalation” mechanism. Furthermore, the CD titration experiment of Zn-
TMPyP4 to hTel22 also ruled out the possibility of the “intercalation” mechanism during 
which some attenuation of the CD signal are often observed at characteristic wavelengths 
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for hTel22 G-quadruplex. A plausible explanation for two binding events, as observed for 
the interactions of Zn-TMPyP4 to hTel22 in K+ salt, may be the preferential binding of 
Zn-TMPyP4 toward one hTel22 foldamer over the others. 
Ni-TMPyP4 and Cu-TMPyP4 exhibit many similarities in comparison to apo-
TMPyP4 with respect to their binding to hTel22 under both Na+ and K+ conditions. First, 
their titration experiments all contain the first reaction in the early part of the titrations 
(between 0 and 1 mol ratio) followed by the “checkmark” pattern. Secondly, the entropic 
contribution dominates the second reaction while the enthalpic contribution is the main 
driving force for the third reaction. These thermodynamic signatures, in combination with 
CD titration experiments, are in very good agreement with a process in which formation 
of the “end-stacking” complex is followed by the “intercalative” complex. The difference 
arises from comparing the thermodynamics of the first reaction in Na+ buffer versus the 
K+ buffer. The enthalpic change is the main driving force for the first reaction of binding 
either Ni- TMPyP4 or Cu-TMPyP4 to hTel22 G-quadruplex in Na+ buffer. The complete 
opposite is observed for the first reaction of binding either Ni-TMPyP4 or Cu-TMPyP4 to 
hTel22 G-quadruplex in K+ buffer in which the entropy change is the main driving force. 
This trend is very similar to thermodynamics of the first reaction during the binding of 
apo-TMPyP4 to hTel22 (see Table 3.1). With the original speculation that the first 
reaction is initially ligand binding coupled with a conformational reorganization of the 
hTel22, the difference in the thermodynamics of the first reaction, as observed in the Na+ 
salt versus the K+ salt, must arise from the difference in the hTel22 pool of foldamers in 
Na+ vs. K+ containing solutions. 
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The question to be asked is why Ni-TMPyP4 or Cu-TMPyP4 behave similarly to 
apo-TMPyP4 with respect to their interactions with hTel22 while Co-TMPyP4 or Zn-
TMPyP4 behave very differently. These differences must be due to the metal ion and the 
coordination geometry and ligand environment around the metal center in metallated-
TMPyP4, in comparison to apo-TMPyP4. Zn-TMPyP4 has been reported to have two 
axial ligands coordinating in an octahedral environment, (27) thereby hindering its ability 
to effectively form a π–π stacking with the G-tetrads, resulting a lower binding affinity 
toward hTel22, as well as completely inhibiting the formation of the intercalative 
complex. Ni-TMPyP4 is in a very fast equilibrium between the unbound (4 coordinate, 
square planar) and diaqua (2 × H2O, 6 coordinate, octahedral) complexes (28, 29). This 
very fast equilibrium can be re-established to favor the unbound square planar geometry 
of Ni-TMPyP4, which is capable of forming “end-stack” as well as “intercalative” 
complexes with hTel22 G-quadruplex. Cu-TMPyP4 has no obstacle for binding from 
axial ligands as its preferred coordination geometry is square planar (28). The higher 
affinity for Cu-TMPyP4 toward hTel22 in comparison to the apo-TMPyP4 may also 
come from additional orbital interactions between the metal ion and the oxygen atoms 
from the guanines of the G-tetrads. Lastly, Zn-TMPyP4 has strongly bound axial water in 
a square pyramidal environment, causing a decrease in affinity for end-stacking and 
inhibiting the intercalative mode (30). 
This study employed isothermal titration calorimetry, in combination with ESI-
MS and CD spectroscopy, to investigate the interactions between a apo-TMPyP4 and a 
series of metallated-TMPyP4 compounds (Co3+, Ni2+, Cu2+, and Zn2+) and the human 
telomeric G-quadruplex. The interactions between apo-TMPyP4 and the hTel22 alone, 
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measured by ITC, are more complex than originally expected. The additional complexity 
seems to be explained on the basis of the topological diversity presented by the hTel22 
G-quadruplex. The differences in the binding of the M-TMPyP4 ligands seem to lend 
additional support for the two binding mode model previously proposed. The two mode 
model incorporating both “end-stacking” and “intercalative” binding mechanisms seems 
to explain the differences in the interactions of the apo-TMPyP4, Ni-TMPyP4, and Cu-
TMPyP4 ligands with hTel22 G-quadruplex DNA and the interactions of the Co-
TMPyP4 or Zn-TMPyP4 ligands with the hTel22 G-quadruplex construct. In addition, 
the higher affinity exhibited by Cu-TMPyP4 (over apo-TMPyP4) may provide a basis for 
the development of better G-quadruplex interactive ligands. 
This study provide lessons regarding both the utility and the limitations of the ITC 
technique for the measurement of the thermodynamic parameters, K (or ΔG), ΔH, −TΔS, 
and n, for a weak (non-covalent) interaction of interest. The power of the 
microcalorimetry technique lies in the fact that most reactions proceed with either the 
evolution or the absorption of heat (i.e. the microcalorimeter is a universal detector). The 
limitation of the microcalorimetry technique is that other techniques must often be used 
in combination with the microcalorimetry technique in order to identify the origin of the 
measured heat effects. Another point to be made from the present study is that the results 
of an ITC study will almost always be model dependent in that a thermodynamic model 
must be used to deconvolute the observed thermograms into a set of best fit 
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THE THERMODYNAMIC EFFECTS OF LIGAND STRUCTURE ON THE 
MOLECULAR RECOGNITION OF RUTHENIUM COMPLEXES  
WITH B-DNA 
4.1 Abstract 
Ruthenium(II) complexes have garnered increasing interest over the last 20 years 
including investigations into their properties as chemosensors and chemotherapeutic 
agents.  Some polyheterocyclic ruthenium compounds have shown less toxicity and are 
able to overcome the resistance seen with platinum drugs.  Due to the hypoxic 
environment present in a broad range of tumors versus normoxic cells, 
[Ru(phen)2(tatpp)]2+ (MP) is able to abstract a hydrogen atom from a DNA backbone 
deoxyribose, resulting in DNA cleavage. The binding mode of mononuclear 
[Ru(phen)3]2+ (Rp3) has been thoroughly examined and is reported to bind via minor 
groove association while [Ru(phen)2(dppz)]2+ (Rp2d) is able to intercalate. Le et al. 
recently reported on the binding of binuclear [(phen)2Ru(tatpp)Ru(phen)2]4+  (P4+) which 
had a greater binding affinity for duplex DNA than Rp3 and bound through an 
intercalative mode.  To further understand the role of the intercalative ligand substituent, 
Ru2+ compounds were examined, starting at Rp3 and building to P4+, and the primary 
binding events for all ligands were entropically driven with either low or unfavorable 
enthalpic contributions. The binding affinities to duplex DNA followed as Rp3 < P4+ < 
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Rp2d < MP.  A second binding mode, two orders of magnitude weaker than the first, 
was seen for Rp2d.  
4.2 Introduction  
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 
years including examination in clinical trials and compared to platinum drugs, the 
complexes based on ruthenium are often identified as less toxic and capable of 
overcoming the resistance induced by platinum drugs in cancer cells (1-4).  Ruthenium 
complexes have shown selective activation to more reactive species by the reducing 
environment of solid tumors as compared to healthy tissues (5-7).  Numerous studies 
have noted the important aspects of the photophysical properties of these ruthenium 
complexes (8-12). 1-5 2-6 
Ruthenium(II) containing drug [Ru(phen)2(tatpp)]2+ (MP) showed promising 
results in a 60 day tumor regression trial that examined the growth of solid tumors in 
H358 bearing mice treated with the Δ enantiomer of MP.  Results of this study included a 
greater than doubled subject survival time and a marked decrease of 83% less tumor 
growth compared to the untreated control (7).  Additional studies measuring the acute 
toxicity of MP in animals showed that low toxicity existed at the doses needed in 
therapeutic treatment. 
Reports furthering the understanding of the mode of action of these drugs have 
indicated that its primary function arises through H-atom extraction in a deoxyribose by a 
carbon radical on the tatpp ligand, causing DNA cleavage (7, 13). Dioxygen, present in 
only low levels in hypoxic tumor cells compared to normoxic cells, is able to quench the 
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radical, leading to selective cleavage of DNA in malignant cells versus healthy, normally 
functioning cells, as seen with the non-reactivity in healthy tissues (7, 13).  
Prior publications by the Lewis group and others have examined the 
thermodynamic parameters involved in the binding of ruthenium(II) containing structures 
(14).  Reports by Chaires’ group examined the binding relationship of mononuclear 
ruthenium(II) complexes and proposed that [Ru(phen)3]2+ (Rp3) bound through a non-
intercalative mechanism, but that by building upon one of the phenanthroline groups, 
forming [Ru(phen)2(dppz)]2+ (Rp2d), intercalation was possible and favored. Le et al. 
previously reported that [(phen)2Ru(tatpp)Ru(phen)2]4+ (P4+) bound to DNA through an 
intercalative binding mode that took advantage of the dynamic “breathing” exhibited by 
duplex DNA.  This present work set out to examine how increasing the size of the 
modified phenanthroline would affect the binding of these ruthenium(II) containing 
complexes using ITC to extract the entirety of the binding thermodynamics and to 
supplement those with CD experiments to validate the changes in structure.   To our 
knowledge, no other groups have published studies examining the structure function 






Figure 4.1 Structures of the Ru2+ compounds used in this study. 
P=[(phen)2Ru(tatpp)Ru(phen)2]4+, MP=[Ru(phen)2(tatpp)]2+, Rp2d=[Ru(phen)2(dppz)]2+, 
Rp3=[Ru(phen)3]2+ 
 
4.3 Material and methods 
The target DNA was 25 base pair dsDNA (25bp duplex) (5′-ATC AAG CTA 
CGG TCT GTG AGC AAG T-3′/5′-ACT TGC TCA CAG ACC GTA GCT TGA T-3′) 
purchased from Midland Certified Reagent Co. as the RP grade and used without further 
purification. The 25bp duplex was exhaustively dialyzed against 80 mM Na+ BPES 
buffer (50 mM NaCl; 10 mM Na2HPO4; 10 mM NaH2PO4; 1 mM EDTA) at pH = 7.0 
and annealed by heating to 95 oC and holding for 10 minutes followed by cooling to 5 °C 
at a rate of 0.5 °C/min. 
Ligands were dissolved in the final dialysate buffer and their concentrations 
calculated from mass of ligand used MP = 1018.9 g/mol; [Ru(phen)2dppz]2+ (Rp2d) = 
814.69 g/mol; [Ru(phen)3]2+ (Rp3) = 712.59 g/mol). Working solutions were made fresh 
prior to experiments by dissolution of the weighed solid into the final dialysate and kept 
at RT in a drawer away from ambient light.  [Ru(phen)2dppz]2+ required substantial heat 
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and sonication to dissolve completely into the buffer systems.  MP required initial heat 
and sonication to dissolve.  [Ru(phen)3]2+ readily dissolved in the chosen buffers. 
ITC experiments were performed using a Microcal VP-ITC (Malvern) at 25 oC. A 
typical experiment involved injection of 28 aliquots of dilute ligand (nominally 120 to 
850 μM) into the calorimeter cell containing 1.45 ml of 10 μM DNA.  Injection volumes 
were 10 μl and injections were made at 200 second intervals. The ITC thermograms were 
corrected for titrate and titrant dilution effects by performing the appropriate blank 
experiments and correcting the observed heats by subtracting the heats of dilution.   
Corrected ITC titrations were fit with a nonlinear regression algorithm using CHASM, an 
ITC data analysis program developed in the Lewis laboratory (15).  
CD experiments were performed using an Olis DSM-20 spectropolarimeter 
(Bogart, GA). Typical experiments involved the titration of ligand into a DNA sample 
with a nominal A260 = ~1. Corrections were made by subtracting the signal of ligand 
titrated into buffer from its respective sample and converting to molar ellipticity.  
ESI-MS experiments on 7 base pair hairpin (7bpHP) and the (Ligand·7bpHP) 
complex were carried out on a Bruker MicrOTOFQ mass spectrometer. Data acquisition 
was set to operate in negative ion mode. All experiments were performed in 50 mM 
ammonium acetate buffer (pH = 7.0) containing 20% HPLC grade methanol. The 7bpHP 
sample was prepared at a concentration of approximately 40 μM in the ammonium 
acetate buffer and was exhaustively dialyzed at 4 °C. Stock solutions of the ligands were 
prepared in the same final dialysate buffer. The ESI-MS samples were prepared by 
mixing the hairpin DNA and ligand stock solutions to yield a mixture containing 4 
equivalents of ligand molecules per molecule of hairpin DNA. The MS capillary voltage 
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was set to +4000 V, dry N2 gas flow was adjusted to 4 L/min at 190 °C, and the sample 
was directly infused into the MS by using a kD Scientific syringe pump set to a flow rate 
of 180 μL/h. Data processing was performed by using the Bruker Daltonics Data 
Analysis program.  
Molecular modeling was performed by Clinton G. Mikek who used Discovery 
Studio 3.1. DNA-ligand molecules were drawn using the internal build functions, 
calculated with the CHARMm force field, and minimized with an implicit solvent model 
dielectric constant of 80.  
4.4 Results 
Le et al. previously reported on P4+ binding to B-DNA with an average affinity of 
~ 4 × 105 M−1 through an entropically driven intercalative mechanism (14).  This work 
seeks to present data on structural derivatives of this parent compound. MP, Rp2d, and 
Rp3 are structurally similar to the original P4+ with the exception of truncation of the 
structure to form a shorter tatpp, dppz, or phen protrusion from the [Ru(Phen)2]2+ base 
and exclusion of the second Ru2+ in the case of MP. 
Table 4.1 summarizes the ITC data collected from the titration of concentrated 
ligand into a dilute sample of DNA in Na+ BPES buffer, while Table B.1 repeats this in 
Tris buffer.  ITC derived data for the binding of MP to DNA show an n value which is 
equal to the 12-13 sites available by observation of the nearest neighbor exclusion for 25 
bp duplex. This was a racemic mixture of MP containing Δ and Λ molecules. 
Experiments with the enantiomerically pure MP would be worthwhile to ensure 
conformity across the enantiomers. MP binding is characterized in this study by a small 
enthalpic penalty against a larger entropic driving force resulting in a value for ΔG of -9.1 
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kcal/mol. The profile for MP binding to 25 bp duplex DNA is similar to that for binding 
of P4+ in which the previously reported formation of P4+·DNA complexes were 
entropically driven (−TΔS  = −9.7 kcal/mol) with an unfavorable enthalpy change (ΔH = 
2.0 kcal/mol) resulting in a value for ΔG of -7.1 kcal/mol. 
Rp2d binding is an entropically driven intercalative process which was previously 
demonstrated (16). The Ka values of 1.4 x 106 M-1  and 8 x 104 M-1  for this racemic 
mixture in the studied buffers are in agreement with data previously collected on the 
enantiomers, which was Ka = 3.2 x 106 M-1  and 1.7 x 106 M-1 for Δ and Λ isomers 
respectively (16). The total stoichiometry is in line with the ~13 molecules that would be 
expected to bind through intercalation limited by neighbor exclusion (17-20).  
Rp3 enantiomers were previously found to weakly bind DNA with binding 
affinities of 4.9 x 104 M-1 and 2.8 x 104 M-1 for the Δ and Λ isomers respectively (21). 
This racemic mixture was found to bind to DNA with a binding constant of 
approximately 1.3 x 104 M-1. Binding was previously reported to be electrostatic in nature 
and not to proceed via a classical intercalative method (21). The enthalpy was previously 
found to be small in magnitude and positive in sign yielding an overall entropically 
driven binding process (22). Since hydrogen bond acceptors and donors are not included 
in the structure, observed enthalpy changes appear to result from van der Waals contacts, 
electrostatic interactions, and/or effects related to the solvation of DNA (22). These 
observations are consistent with the data reported in this work.  Binding of an Rp3 
molecule was reported to remove 3-4 base pairs as potential binding sites from the DNA 
lattice which is also in agreement with the approximately five molecules that were found 
bound to 25bp duplex DNA in this study (21). 
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Table 4.1 Thermodynamic data obtained from ITC experiments performed at 298 K 
for the interaction between ligands and dsDNA in Na+ BPES buffer 
 
Figure 4.2 shows CD results for the binding of ligand to the target 25 bp duplex 
DNA in Tris buffer.  The signal for the titrations of MP into DNA demonstrates an 
attenuation in molar ellipticity at 274 nm and undergoes a bathochromic shift up to 2:1 
binding.  This bathochromic shift was previously seen in experiments with P4+ binding to 
a 7 base pair hairpin.  Additional ligand shifts the peak to its original wavelength and by 
8:1 the molar ellipticity retains only a fraction of its original intensity. The MP ligand is 
interacting with the DNA in such a way as to disrupt its structure.  This disruption is 
likely in the form of unwinding as the intercalating moiety inserts itself between base 
stacked bases.  Figure 4.3A shows MP bound to the minor grove of DNA and the 
displacement of the nucleotide bases to accommodate the intercalation taking place.  
Elongation of the duplex has occurred to accommodate the intercalation in these 
simulations.  
Rp2d titrations demonstrate a hypsochromic shift from 275 to 260 nm for the CD 
signal.  This 260 nm region is characteristic of A-DNA character, in which the minor 
groove has been elongated (23).  This suggests the major groove is changing as a result of 
binding. This binding mode is illustrated in Figure 4.3B, modelled with ligand binding 
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directionally from the minor groove of DNA and one ligand molecule lying in the major 
groove. 
Rp3 titration experiments do not demonstrate attenuation. This is consistent with 
a non-intercalative mode of binding.  Chaires previously demonstrated that Rp3 binds to 
the major/minor groove of DNA (21, 22).  This binding mode is shown in Figure 4.3C. 
Figure B.1 repeats the CD experiments in BPES buffer and appears very similar to the 
experiments in tris buffer.  
As shown in Figure 4.4, the ESI mass spectra observed in the presence of the 
various ligands differs from that of the original DNA (shown in Figure 4.4A or 4.4C). 
Figure 4.4D shows notable m/z peaks at 1598.2, 1833.9, 2131.3, and 2446.3 which 
correspond to DNA*MP complexes of 1 or 2 molecules of MP per molecule of 7 bpHP. 
Figure 4.4E shows notable m/z peaks at 1386.2, 1547.2, 1732.7, 1939.2, 2063.3, and 
2310.3 which correspond to DNA*Rp2d complexes of 1, 2, or 3 molecules of Rp2d per 
molecule of 7 bpHP. Notable m/z peaks in Figure 5.4F are 1521.7, 1681.7, 1841.7, 
2029.2, 2242.6, and 2455.6 which correspond to DNA*Rp3 complexes of 1, 2 or 3 












Figure 4.3 Minimized models of MP (A), Rp2d (B), and Rp3 (C) interacting with 






Figure 4.4 ESI-MS of free hairpin DNA and hairpin DNA incubated with a slight excess of the indicated ligand. DNA 




Previous reports have indicated that 1,10-phenanthroline and related analogs are 
capable of interacting with DNA through an intercalative binding mode.  Complexation 
of several phenanthroline molecules to a metal center was previously thought to have a 
partial intercalative mode as well (16).  Chaires was able to demonstrate that 
[Ru(phen)3]2+ binding does not proceed through the classical intercalative mode, but 
rather through Van der Waals contacts, electrostatic interactions, and/or effects related to 
the solvation of DNA (16).  Le et al. reported that P4+ was able to interact with DNA with 
an affinity one order of magnitude greater than the Rp3 binding, but that the enthalpy 
was similar to that reported by Chaires group.  Le et al. presented that P4+ was able to 
thread through the DNA base pairs by taking advantage of the “breathing” motion of 
DNA (14).  Interestingly, the kinetics of the reaction appeared to be relatively fast for a 
threading mechanism, perhaps due to the dynamic flux of DNA.  To further understand 
this intercalative binding mode, MP, Rp2d, and Rp3 (ligand size starting at phen and 
building towards tatpp) were bound to 25bp duplex to examine the structure function 
relationship of the Ru2+ ligands with DNA. 
As a starting point, the validity of 25 bp duplex DNA as a good model DNA was 
confirmed by comparing the experiments with Rp3 in this work to the literature.  For 
Rp3 binding to 25 bp DNA, a similar binding affinity with respect to the previous reports 
for the forward titration experiment was obtained (21).  Additionally the measured 
enthalpy agrees with the results for their Rp3 binding (both were positive, difference was 
~0.1 kcal/mol) and the entropic contribution were comparable (ΔS= 28.8 vs 26.8 cal/mol) 
especially considering the buffer concentrations differed from their system (16).  
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Further building upon the Rp3 scaffold, the binding of Rp2d was examined.  Two 
distinct binding events were noted.  The first higher affinity binding of 1.2 x 106 was 
comparable to that reported by Chaires et al. (16).  Interestingly this work yielded a 
negative enthalpy, whereas their reported enthalpy for the binding of Rp2d was 0.2 
kcal/mol vs this work’s -1.1 kcal/mol, but both obtained a favorable entropic contribution 
(16).  The difference in enthalpy is small and possibly negligible, but could arise from a 
number of factors including the difference in buffer conditions or the differences arising 
from the use of different techniques (the entirety of the presented thermodynamic 
parameters were derived from ITC, whereas Chaires et al. only reported enthalpies from 
ITC and used fluorescence data for the binding constants) (16).  Recent advances in 
microcalorimetry and the fitting models used to model the binding parameters could also 
explain this difference.  Nevertheless, using these different models with different DNAs, 
similar binding affinities were obtained.  
Interestingly, a secondary binding event which was not reported by Chaires et al. 
was observed.  Similar results of a second binding event were seen in more recent ITC 
results of Rp2d with (poly[dAdT])2  by Lincoln et al., where they saw two distinct 
binding events via ITC but did not present the values of the thermodynamic parameters of 
the second binding event (24).  This work’s ITC derived first binding site free energy 
change value is nearly identical to their reported value, and both determined the first 
binding mode to be entropically driven.  The second binding mode was characterized by 
a more favorable enthalpic contribution, as was also stated by Lincoln et al., with an 
almost equal entropic contribution.  While we agree with the assignment of the nature of 
the primary ligand binding by Lincoln et al., we do not believe the additional mode to 
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simply be that of a canted geometrical binding, but rather a side-on interaction with the 
backbone of the DNA or a new intercalative association arising from the original 
intercalation which caused a widening of the minor groove (25, 26).  
Thermodynamically, a normal and canted intercalation should be relatively similar and 
instead two separate binding modes with distinctly different enthalpic and entropic 
contributions were observed (27).  X-ray crystal structures of both ∆ and Λ complexes 
with DNA are available and show two different binding modes for the racemic mixture 
(28).  Additional crystal structures show the structural variance possible in bound DNA at 
differing relative humidities (25).  It should be noted that this difference could arise from 
the different oligonucleotides used in the two studies.  Future ITC titrations with full 
thermodynamic characterization of both binding events with [poly(dAdT)]2 would be 
useful to compare these two systems.  We do not believe the difference in the ITC profile 
to be the result of a competitive process between these two modes though, as the two are 
added simultaneously and the affinities for both processes are two orders of magnitude 
different (29).  
In order to complete the link between Rp3 and P4+ the interaction of MP with the 
model duplex DNA was examined.  A slightly higher binding constant, suggesting a 
more favorable interaction for MP with duplex DNA than Rp2d with duplex DNA, was 
obtained for MP vs Rp2d.  This higher association for the intercalated construct likely 
arises not only from the favorable π-π interactions of the extended conjugated system but 
also due to the release of unfavorable hydrophobic interactions between the ligand and 
solvent system (water) upon binding of the ligand to DNA.  Molecular dynamics energy 
minimization studies show a closer relationship between the MP Ru2+ center and the 
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nucleotides than was observed with the modeling of P4+ complexed with the same DNA. 
Perhaps the majority of the additional binding energy comes from this ability to more 
closely associate with the backbone and have more favorable ionic interactions instead of 
two cationic metal centers competing for the interaction and having a less 
thermodynamically stable binding product.  
CD titration results assisted in the confirmation of these conclusions. Rp3 shows 
little to no effect on the structure of the duplex, as there is no large amount of absorbance 
shifts observed. Figure 4.3C shows the Rp3 ligand associating with the grooves of DNA.  
Creating an extension from the phenanthroline ligand offers an intercalative ability with a 
higher affinity.  This increased affinity for the bound mode causes structural changes 
through steric interactions between the bulky phenanthroline groups and the DNA 
backbone as well as deformation caused by the necessary increase in distance between 
base pairs to accommodate the intercalation.  For the binding of Rp2d to DNA, the minor 
groove is likely widened to near A-form type as seen with the emergence of a positive 
peak near 260-270 nm, which is indicative of A-form DNA (23, 30).  Figure 4.3B shows 
Rp2d intercalating into DNA from the minor groove and widening it to accommodate the 
phenanthroline groups lying in the grove. A minor groove binding non-intercalative mode 
is also demonstrated in the figure. Increasing the width of the minor groove and major 
grooves is necessary for relaxation of the torsional strain caused by intercalation (31).  
With the case of MP, there is a drastic attenuation in molar ellipticity in the 
region of 275 nm in both buffers examined. Titrations of MP in phosphate buffer 
demonstrated emergence of a positive peak near 260-270 nm at mole ratios of ligand in 
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excess of the 8 expected for a 25 base pair duplex that would be able bind based on the 
Rp3 exclusion observation discussed by Chaires et al. (21).   
4.6 Conclusion 
The reported ITC, ESI-MS, and CD results from the experiments serve to 
examine the structure function relationship of these Ru2+ ligands when binding with 
DNA.  A marked increase in binding affinity for the mononuclear Ru2+ containing 
ligands that are able to intercalate versus the mononuclear Rp3 which has been reported 
to not bind through classical intercalation was seen.  The favorable entropic contributions 
likely arise from the displacement of solvent (water) upon ligand binding, as well as the 
unwinding of the duplex.  ESI-MS data support the “neighbor exclusion principle” and 
exclusion based on the size of Rp3 that has been previously reported (14, 21).  
MP binds to dsDNA with an affinity 1.5 kcal/mol greater than that of P4+, while 
Rp2d binds with an affinity slightly lower than that of P4+, suggesting that a longer 
intercalating moiety but not additional groove binding moiety is able to enhance the 
binding of these Ru2+ containing DNA binding ligands.  Future studies will examine 
more substituted ligands as well as the enantiomerically pure samples of Rp2d and MP 
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A.1 Complete ITC titration profiles 
 
Figure A.1 Representative ITC titration profile for the titration of apo-TMPyP4 into 




Figure A.2 Representative ITC titration profile for the titration of Cu-TMPyP4 into 




Figure A.3 Representative ITC titration profile for the titration of Ni-TMPyP4 into 




Figure A.4 Representative ITC titration profile for the titration of Co-TMPyP4 into 




Figure A.5 Representative ITC titration profile for the titration of Zn-TMPyP4 into 




Figure A.6 Representative titration profile for the dilution of apo-TMPyP4 in 150 mM 





Figure A.7 Representative titration profile for the dilution of Cu-TMPyP4 in 150 mM 
K+ BPES buffer.  





Figure A.8 Representative titration profile for the dilution of Ni-TMPyP4 in 150 mM 






Figure A.9 Representative titration profile for the dilution of Co-TMPyP4 in 150 mM 





Figure A.10 Representative titration profile for the dilution of Zn-TMPyP4 in 150 mM 





Figure A.11 Representative ITC titration profile for the titration of apo-TMPyP4 into  




Figure A.12 Representative ITC titration profile for the titration of Cu-TMPyP4 into 




Figure A.13 Representative ITC titration profile for the titration of Ni-TMPyP4 into 




Figure A.14 Representative ITC titration profile for the titration of Co-TMPyP4 into 




Figure A.15 Representative ITC titration profile for the titration of Zn-TMPyP4 into 




Figure A.16 Representative ITC titration profile for the dilution of apo-TMPyP4 in 150 
mM Na+ BPES buffer.  





Figure A.17 Representative titration profile for the dilution of Cu-TMPyP4 in 150 mM 
Na+ BPES buffer.  





Figure A.18 Representative titration profile for the dilution of Ni-TMPyP4 in 150 mM 
Na+ BPES buffer.  
Note the low exothermic heats of dilution seen. 




Figure A.19 Representative titration profile for the dilution of Zn-TMPyP4 in 150 mM 
Na+ BPES buffer.  




A.2 Titrations at 60 mM supporting electrolyte 
In addition to the published work, titrations at 60 mM supporting electrolyte 
concentration were performed.  Below are those data compared to the published data for 
apo-, Cu-, and Zn-TMPyP4 
 
Figure A.20 Representative ITC titration enthalpogram for the titration of apo-TMPyP4 
into hTel22 in 60 or 150 mM Na+ or K+ BPES buffer.   




Figure A.21 Representative ITC titration enthalpogram for the titration of Ni-TMPyP4 
into hTel22 in 60 or 150 mM Na+ or K+ BPES buffer. 




Figure A.22 Representative ITC titration enthalpogram for the titration of Cu-TMPyP4 
into hTel22 in 60 or 150 mM Na+ or K+ BPES buffer 




A.3 Circular dichroism spectra for titrations 
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B.1 ITC final figures 
 






Figure B.2 Representative ITC titration profile for the titration of MP into 25 bp 









Figure B.4 Representative ITC titration profile for the titration of Rp2d into 25 bp 








Figure B.6 Representative ITC titration profile for the titration of Rp3 into 25 bp 









Figure B.8 Representative ITC titration profile for the titration of MP into 25 bp 









Figure B.10 Representative ITC titration profile for the titration of Rp2d into 25 bp 









Figure B.12 Representative ITC titration profile for the titration of RP3 into 25 bp 







B.2 Circular dichroism spectra for titrations 
 

















Table B.1 Thermodynamic Data obtained from ITC Experiments performed at 298 K 
for the interactions between ligands and 25bp duplex in tris buffer. 
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